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 Acute lung injury and adult respiratory distress syndrome are 
characterized by pathological efflux of serum proteins and fluid from capillaries to 
interstitial tissues and represents a significant complication in the clinical setting 
with no mitigating therapy.  The scope of this research is to lay the foundation for 
a polymer-based therapy, delivered to inflamed vascular endothelium, that 
strengthens the capillary barrier.  The research spans the use of two polymer 
prototypes. The first polymer prototype, a tetramethylammonium chloride 
copolymer with a poly-N-(2-hydroxypropyl)methacrylamide (P-HPMA) backbone 
that binds to endothelium via ionic interactions, is used to show the efficacy of 
copolymer delivery to highly permeable endothelium.  The second polymer 
prototype retains the HPMA backbone but exchanges cationic side chains for a 
peptide that targets E-selectin, an endothelial protein that is upregulated during 
inflammation and mediates leukocyte tethering and rolling.  In this work, we are 
able to show a significant reduction in solute and solvent flux across endothelial 
monolayers under cytokine-mediated or mechanical stress in the presence of 
copolymers.  We determined that the attenuation of barrier permeability was due 
to the polymer’s inhibition of cell signaling mechanism(s) and not only a result of 
an increased physical barrier.  The administration of copolymers attenuates 
capillary permeability in an ex vivo lung model to demonstrate the viability of
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 targeted copolymer delivery to vascular endothelium as a treatment for vascular 
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INTRODUCTION TO VASCULAR PERMEABILITY  
 
AND A POLYMER BASED THERAPY 
 
 
 Acute lung injury (1) and its extreme disease state, adult respiratory 
distress syndrome (ARDS), continue to represent a major source of morbidity 
and mortality in the clinical setting.  ALI/ARDS can arise from a variety of medical 
complications such as ischemia/reperfusion injury, mechanical stress resulting 
from ventilator-induced injury, pneumonia, sepsis, blunt chest trauma, 
cardiopulmonary bypass surgery, and organ transplant. ALI/ARDS is 
characterized by severe oxygenation impairment accompanied by a pathological 
efflux of fluid and serum proteins from the capillaries into interstitial tissues along 
with the release of cytokines and inflammatory mediators that, over time, have a 
deleterious effect on the microvascular capillary environment. A current treatment 
for ALI/ARDS does not exist beyond ventilator strategies.  The ultimate goal of 
this research is the development of a clinically viable treatment for pulmonary 









1.1 Capillary physiology 
 
 The endothelial glycocalyx is a multifunctional layer of entangled 
glycoproteins, glycolipids, and glycosaminoglycans that coats the surface of 
vascular endothelial cells and cell junctions.  It is approximately 2-3 "m in 
thickness (2) and acts as both an active and passive barrier that regulates 
adsorption and extravasation of serum proteins and actively participates in signal 
transduction to temper vascular tone (3).  Both of these functions are altered in 
the presence of acute inflammation (4, 5). 
 Passively, the glycocalyx is composed of a dense matrix of membrane-
bound and intercalated macromolecules.  It has a net negative charge due to its 
extensive concentration of bound anionic moieties such as sialic acids, carboxyl 
groups and sulfated carbohydrates.  This polyanionic nature facilitates 
association with cationic plasma proteins, enzymes, growth factors, amino acids, 
and water; therefore, the glycocalyx can behave as a selective permeability 
barrier for macromolecules based on size and charge (3). 
 The active role of the glycocalyx involves key glycosaminoglycans such as 
heparan sulfate (6), hyaluronan (HA), and chondroitin sulfate (CS).  These 
glycans are linear heteropolysaccharides that are identified by distinct 
disaccharide unit repeats.  Heparan sulfate is the most extensively studied GAG 
(2, 7, 8) and is prominently featured on the endothelial surface, comprising 
roughly 50% of the total GAG content (9).  Heparan sulfate is an oligosaccharide 
found on syndecan, a transmembrane proteoglycan, as well as on membrane-
associated glypicans and perlecans (10) and has highly sulfated domains 
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interspersed in regions of moderate and low sulfation.  The biosynthesis of 
heparan sulfate is highly controlled to create a specific fine structure and it is 
hypothesized that the sulfation pattern on heparan sulfate carbohydrate chains 
may function as receptors for specific ligands.  Transmembrane syndecans 
contact the cytoskeleton through "-actinin and are capable of signal transduction 
through protein kinase C.  Syndecans are also implicated in actomyosin 
contraction through RhoA and Rho kinases.  These characteristics alone 
implicate heparan sulfates and syndecan as mechanical sensors (11). 
 Hyaluronan (HA) is a secreted GAG that remains on the cell surface and 
intercalates into the glycocalyx while CS is found on syndecan as well, although 
typically closer to the cell membrane (10).  Degradation of HA results in 
heightened macromolecular permeability of the glycocalyx (5) and its rheological 
properties have been implicated in its role as a mechanosensor (12). Enzymatic 
degradation of hyaulronan attenuates flow-mediated nitric oxide production but 
does not prevent against agonist-induced NO production via acetylcholine 
administration, indicating that HA is part of the mechanosensing apparatus on 




 The mechanism by which extracellular forces are translated into signal(s) 
that are relayed to junctional proteins to allow efflux of fluid and proteins from the 
capillaries has been extensively studied (3, 14, 15) yet is poorly understood.  A 
conceptual model of how fluid flow elicits a cellular response describes the GAG 
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components of the glycocalyx as drag sensors that transmit force from capillary 
blood flow to core surface proteins.  The signal is propagated to the plasma 
membrane or the actin cytoskeleton (3).  Capillary endothelial cells are subjected 
to two types of stress vectors: a stress perpendicular to the vessel wall attributed 
to blood pressure and a stress parallel to the vessel wall due to hemodynamic 
shear as blood flows along the capillary.  In the case of hemodynamic shear, the 
model predicts that fluid shear stress is transmitted to the membrane-associated 
or transmembrane protein components of the glycocalyx, which deliver the force 
to the cell (3).  This model has been corroborated in the studies conducted by 
Weinbaum et al. (16) in which core proteins of the glycocalyx are modeled as 
sufficiently rigid to resist bending in the presence of shear and to transmit force-
mediated perturbations to the actin cortical skeleton via transmembrane 
domains.  Cumulative GAG-mediated displacements of individual actin filaments 
in the cortical web are on the order of 10 nm for typical fluid shear, which are 
hypothesized to be a factor in signal transduction (6). 
 The relationship between the glycocalyx and mechanotransduction has 
been probed primarily through experiments in which components of the 
glycocalyx are enzymatically degraded and function is reassessed.  Florian et al. 
used heparanase III to degrade heparan sulfate chains on endothelial cells and 
reported complete inhibition of increases in nitric oxide production in response to 
fluid shear stress (7). In their seminal paper, Pahakis et al. (8) removed heparan 
sulfate, chondroitin sulfate, hyaluronan, and sialic acid, independently, and 
measured nitric oxide output from endothelial monolayers under the influence of 
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shear stress.  The increased production of nitric oxide in response to shear 
stress was attenuated by the removal of heparan sulfate, sialic acid, and 
hyaluronan, but not chondroitin sulfate.  This directly implicates specific GAGs as 
signal transducers.  It was also shown that none of the enzymes used had an 
inhibitory effect on the shear-induced production of prostacyclin (PGI2), which 
suggests multiple mechanisms for mechanotransduction (8).  
 The relationship between forces exerted on the glycocalyx and actin 
cytoskeleton rearrangement was shown when magnetic beads, covalently bound 
with RGD sequence-bearing peptides, were allowed to bind to the glycocalyx.  
The application of a strong external magnetic field resulted in an applied torque 
to the beads and the resistance to bead rotation was taken as an indication of 
cell stiffness.  Disruption of the microfilament lattice with cytochalasin D and the 
disruption of microtubules with nocodaxole fully inhibited the stiffening response 
(14).  In experiments that visualize the spatial displacement of key cell junction 
proteins using confocal microscopy, shear stress has been shown to rearrange 
F-actin, vinculin, paxillin, and the tight junction protein ZO-1 (15).  These findings 
are a few in a large body of work that implicates mechanical perturbations to the 
glycocalyx in signal transduction and cell junction integrity. 
 
1.3 Polymer-based therapy 
 The research contained in this dissertation outlines the development of a 
water-soluble biomimetic polymer delivered to the vascular endothelium to 
dampen the mechanical perturbations experienced by the glycocalyx and, 
thereby, turn off mechanotransduction pathway(s). Mounting evidence suggests 
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that the benefit of glycocalyx stiffening may mitigate capillary permeability; 
therefore, an HPMA-based polymer was constructed as a glycocalyx-
intercalating agent.   
 Poly-N-(2-hydroxypropyl) methacrylamide (HPMA) is a water soluble, 
flexible polymer backbone that is capable of conjugation to a variety of targeting 
moieties via reactive side chains.  Kopecek et al. first reported the design and 
synthesis of polymers of HPMA in 1973 (17) and the favorable hydrodynamic 
properties of P-HPMA were described in 1974 (18). [P- denotes a poly-HPMA 
backbone in the nomenclature used throughout this text.]  Since then, HPMA has 
been used to target anticancer drugs to a wide variety of tumors including 
prostate (19), bone (20, 21), ovarian (22), renal (23), colon (24, 25), and T- and 
B-cell lymphomas (26) as well as to the gastrointestinal wall (27) and the tumor 
endothelium itself (28).  In 1999, the doxorubicin-HPMA copolymer PK1 was the 
first HPMA-based copolymer drug conjugate to enter clinical trials as a 
chemotherapeutic agent (29).  Copolymers may target to tumor sites directly 
using targeting agents such as antibodies (30, 31), lectins (27), or peptides (19, 
32) or copolymers may deliver drug conjugates by passive absorption through 
highly permeable tumor neovasculature (22, 33) this phenomenon is known as 
the enhanced permeability and retention effect, or EPR (34).  The advantage of 
drug conjugation to hydrophilic macromolecules is that this reduces the 
nonspecific systemic toxicity of the drug (35, 36) as well as increases the 
systemic half-life of the drug provided that polymer conjugates are larger than the 
glomerular filtration cutoff of approximately 14 Å (37).   
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 In addition to drug targeting and delivery, HPMA scaffolds have been used 
extensively to conjugate cationic residues for the purpose of gene and siRNA 
delivery.  Both uses take advantage of the net negative charge of the cell 
membrane (38) to associate copolymers to the cell surface and thereby trigger 
endocytotic pathways to deliver cargo into the cell.  Seymour et al. have used 
copolymers of HPMA and trimethylammonium chloride to condense DNA for the 
purposes of nonviral gene delivery (39, 40) as well as using a 
trimethylammonium chloride copolymer as a coating on viral gene therapy 
vectors to mask the vector from immune recognition (41).  Tertiary amine-HPMA 
copolymers containing folate conjugates have been used to deliver siRNAs to 
tumor cells (42).  HPMA copolymers bearing triphenylphosphonium cationic 
groups have also been shown to have cell internalization properties (43). 
 HPMA has been used extensively as a copolymer backbone in part due to 
low inherent cytotoxicity (44-46), blood compatibility (44), and stability at 
physiological pH (47).  Immunological studies have shown that P-HPMA does not 
increase antibody concentration in vivo and any immune response occurring in 
the presence of HPMA copolymers is attributed to the side chain (48).  Multiple 
studies have shown a correlation between the intensity of the immune response 
and the molecular weight of the copolymer (45, 46), the composition of its side 
chains (45), the concentration of the copolymer (45) and valence of the conjugate 
when the side chains are known haptens (46).  Dintzis et al. (46) compared 
multiple polymer backbones of varying molecular weights and hapten loading.  
Immunogenicity was relatively independent of the chemical makeup of the 
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polymer backbone and was directly related to the molar mass of the copolymer 
and the hapten valence.  All of the copolymers induced an immune response at 
some hapten loading ratio and molecular weight. Conversely, these same 
copolymers were shown to be nonimmunogenic at different hapten ratios and 
molecular weights (46).   
 In this research, we use HPMA-trimethylammonium chloride copolymers  
as a proof-in-concept tool to describe how associations with HPMA can attenuate 
mechanotransduction; however, we acknowledge the inherent problems with 
using cationic copolymers as a systemic treatment.  Firstly, cationic copolymers 
are used in gene delivery for their excellent access to intercellular compartments 
due to triggering endocytosis.  Liu et al. (49) examined the relationship between 
polymer side chain charge and cellular internalization and ultimate polymer 
localization.  The study determined that strongly basic side chains, in this case 
20 mol% methacryloyloxyethyl trimethylammonium chloride, associated with the 
cell membrane within minutes and were endocytosed via dynamin-dependent 
pathways.  Strongly acidic side chains were endocytosed primary through fluid 
phase endocytosis.  Weakly basic copolymers (2-(N,N-dimethylamino)ethyl 
methacrylate) were endocytosed in a similar manner at a faster rate than were 
negatively charged copolymers of the same charge density.  The disparity 
between the rate of uptake of positively- and negatively charged copolymers 
widened as concentration increased, suggesting a concentration- and charge-
dependent mechanism for cell association and endocytosis.  Rates and 
pathways of endocytosis were found to be independent of the HPMA backbone 
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itself, in accordance with previous conclusions that P-HPMA is relatively inactive 
at the cellular level (49).   
 Secondly, cationic copolymers possess no specific targeting agent and 
therefore may associate with any negatively charged cell or serum proteins to 
form aggregates. Significant aggregation of albumin in whole serum has been 
shown in the presence of poly-L-lysine (pLL).  The zeta potential of pLL/DNA 
complexes decreased sharply from 48 mV for untreated complexes to -16 mV in 
serum (50), indicating albumin association and potential physical trapping in 
microvessels.  Cationic copolymers have also been shown to demonstrate 
significant systemic toxicity and the relationship between structure and systemic 
activity has been reviewed extensively (51, 52). 
 In this research, the first polymer prototype was designed to associate 
with the negatively charged glycocalyx via quaternary ammonium side chains 
conjugated to the HPMA backbone.  We chose quaternary ammonium side 
chains for their reduced cytotoxicity when compared to primary amine 
copolymers.  Reschel et al. (53) studied transfection activity of primary and 
tertiary amino polyanions and quaternary ammonium polyanions and concluded 
that polymers containing primary amino groups demonstrated significantly higher 
gene transfection properties than did quaternary ammonium polycations.  They 
concluded that since successful transfection depends on both endocytosis and 
endosomal release, primary amino polyanions may be better able to disrupt 
endosomal compartment membranes by association with surface phosphate 
groups (53).  This correlates to the reduced cytotoxicity seen in endothelial cells 
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exposed to quaternary ammonium-HPMA copolymers compared to primary 
amino-HPMA copolymers (54).   
 Cationic copolymers were not intended as a permanent solution to 
accomplish P-HPMA binding to endothelial glycocalyx.  However, these 
copolymers were the logical first step in the development of a polymeric construct 
that could interact with the cell surface yet potentially minimize cellular uptake by 
associating loosely through ionic contact.  As the delivery of HPMA-based 
copolymer became a clearly viable avenue for mechanotransduction research, it 
became necessary to develop a targeting strategy that allows delivery of HPMA 
to the glycocalyx but elicits minimal to no adverse physiological response. 
 
1.4 E-selectin 
 The cell surface protein E-selectin has been targeted in a variety of 
settings where the visualization of or delivery to sites of inflamed endothelium is 
desirable, such as tumor targeting (6, 32), siRNA delivery (55, 56), brain 
inflammation (57), arthritis (58), and anti-inflammatory drug delivery (59).  E-
selectin is chosen for targeting in inflammatory diseases and cancer by virtue of 
its upregulation in the presence of inflammation and extended residence time on 
activated endothelium.  The de novo biosynthesis of E-selectin peaks within 2-6 
hours of inflammatory insult and is mediated by cytokines such as TNF-", 
lipopolysaccharides (LPS), and interleukin 1# (IL-1#).  Basal levels of E-selectin 




 E-selectin is primarily found on activated endothelium, whereas P-selectin 
is found on both platelets and activated endothelium and L-selectin is found only 
on leukocytes. E-selectin differs from P-selectin in that P-selectin is stored in 
Weibel-Palade bodies and are upregulated on the cell surface within minutes of 
thrombin or oxygen radical exposure and is released within 30 minutes from 
surface membranes following exposure.  These selectins all have a common 
structural organization composed of the lectin domain at the N-terminus, an EGF-
domain, a domain whose length is dictated by whether the selectin is E, P, or L, a 
transmembrane domain, and a short cytoplasmic C-terminal domain (61).  The 
lectin binding domain is 60% homologous across all selectin subtypes (62).   
 The specificity of E-selectin for sialyl lewis x was demonstrated by Lowe et 
al. in Chinese hamster ovary (CHO) cells (63) and concurrently by Walz et al. 
(64) who examined the ability for E-selectin binding to white blood cells.  An E-
selectin—IgG1 chimera was covalently attached to plastic dishes and incubated 
with granulocytes and myeloid cells.  These cells bound to the E-selectin-coated 
plastic if they were positive for CD15 expression (3-fucosyl-N-acetyl lactosamine) 
whereas dishes coated with a CD8 fusion protein showed negligible affinity for all 
cells tested.  Incubation with neuraminidase abolished the effect, thus 
demonstrating the necessity for fucose presence in E-selectin binding.  
Incubation of the plastic dishes with the sialyl lewis x-determinant CSLEX1 also 
completely inhibited adhesion of myeloid cells to E-selectin (64). 
 Elucidation of carbohydrate ligands for E-selectin was followed by the 
discovery of peptide ligands for E-selectin.  Martens et al. (65) used a phage 
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display to elucidate several sequences that bound to E-selectin with high affinity 
(IC50 values were between 4.0 and 910 nm).  The sequences all conserved 
tryptophan and methionine residues and were determined to bind E-selectin 
independent of Ca2+, which suggested an allosteric binding site distinct from that 
of sialyl lewis x (65).  Shamay et al. (32) later used the peptide sequence from 
this study with the highest affinity for E-selectin to target an HPMA-doxorubicin 
copolymer to immobilized E-selectin and later human immortalized vascular 
endothelial cells (IVECs) in flow cytometry assays.  Conjugating the peptide to 
the copolymer further lowered the binding affinity of peptides to 6 nm by the 
multivalent effect.  These peptide copolymers were shown to localize to 
lysosomes within 15 hours (32), in agreement with studies that found E-selectin-
bound antibodies localized to lysosomes after 4 hours postcytokine exposure 
(66). 
 Beyond its novel targeting capacity, E-selectin also serves as a receptor 
for leukocyte endothelial binding. Bernardes-Silva et al. demonstrated a 
significant reduction in neutrophil recruitment to rat brains that were first injected 
with IL-1# then antibodies to E- and P-selectin (67). The ability to block neutrophil 
recruitment may be exploited in acute lung injury repair as oligosaccharides have 
been conjugated with sialyl lewis x, the endogenous ligand to E-selectin, with the 
intent of blocking leukocyte interactions.  A modest reduction in capillary 
permeability was seen in rat models when injected with these sialyl lewis x-
oligosaccharide conjugates (59).  In a related study, similar sialyl lewis x-bearing 
oligosaccharides demonstrated cardioprotective properties when administered to 
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feline models of myocardial ischemia/reperfusion injury (60). Taken together, 
these experiments demonstrate the benefit of blocking endothelial selectins from 
leukocyte binding.  The potential to sterically block leukocyte binding while 
dampening mechanotransduction with a polymer construct would be highly 
beneficial multifaceted approach to treat vascular permeability and acute lung 
injury.  
 
1.5 Specific aims 
 The specific aims outlined in this dissertation are designed to lay the 
foundation for future research into the mechanism(s) involved in 
mechanotransduction and a clinically relevant treatment for pulmonary edema 
and acute lung inflammation.  Specifically, these aims are as follows: 
1. Aim 1. Develop a polymer construct that demonstrates limited toxicity, 
effective binding to the endothelial glycocalyx, and efficacy in reducing 
fluid and solute flux across endothelial monolayers subjected to 
chemical and mechanical stress. We hypothesize that positively 
charged copolymers can bind to the negatively charged glycocalyx and 
that the use of a poly-HPMA backbone will minimize toxicity and 
reinforce the endothelial barrier. 
2. Aim 2. Characterize the mechanism by which polymer administration 
reduces barrier permeability and to determine whether this mechanism 
falls under the category of passive or active barrier function.  The 
release of nitric oxide (NO) from mechanically-stressed endothelial 
monolayers is indicative of the activation of cell signaling pathways.  
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We hypothesize that the quantification of NO production of endothelial 
cells under mechanical stress in the presence or absence of copolymer 
can determine the capacity of copolymer administration to reduce the 
active barrier dysfunction. 
3. Aim 3. Translate the in vitro polymer findings to an ex vivo whole organ 
model.  We hypothesize that the capacity of copolymer administration 
to reduce the capillary filtration coefficient, the indicator of acute 
pulmonary edema accumulation in pericapillary tissues, can be best 
demonstrated in the presence of all components of pulmonary 
physiology, e.g., a whole lung model. 
4. Aim 4. Optimize the polymer construct to minimize pleiotropic effects 
as may arise from in vivo administration of a cationic copolymer.  We 
hypothesize that cationic moieties can be replaced with E-selectin 
binding ligands that can be used to target polymers directly to areas of 
acute inflammation. 
 The first specific aim is accomplished in Chapters 2 and 3.  A copolymer is 
developed that reduces both solute and protein flux through endothelial 
monolayers under cytokine- and pressure-mediated barrier distress.  This 
copolymer is shown to bind to endothelium and exhibits minimal cytotoxicity as 
compared to other prototypes. 
 The second and third specific aims are addressed in Chapter 3.  Chapter 
3 was published as a companion piece to Chapter 2, wherein both chapters 
exhaust in vitro and ex vivo studies required to demonstrate the utility of the 
15 
 
design of HPMA copolymer delivery to inflamed endothelium. Chapter 3 
addresses the characterization of the mechanism of action of polymer 
administration along with molecular weight requirements for ex vivo functional 
studies. 
 Chapter 4 includes preliminary studies using a second polymer prototype 
that relies on receptor targeting for endothelial delivery as opposed to ionic 
contacts.  This second polymer prototype is intended to begin the optimization 
process for an intravenously delivered therapy.  Chapters 2 and 3 demonstrate 
the potential for HPMA delivery to strengthen the capillary barrier function and 
Chapter 4 comprises preliminary research to target P(HPMA) to areas of 
vascular inflammation. 
 Chapter 5 is a discussion of the conclusions of this dissertation and 
presents the whole picture of the research herein along with suggestions for 








AN ENDOTHELIUM-ASSOCIATED CATIONIC  
COPOLYMER TO ENHANCE BARRIER  




 Biomimetic polymers are hypothesized herein to enhance passive barrier 
function by reducing the porosity of the endothelial glycocalyx and attenuate 
mechanotransduction by restricting the motion of the glycoproteins implicated in 
signal transduction. To this end, cationic copolymers containing 
methacrylamidopropyl trimethylammonium chloride [P(TMA)Cl] have been 
developed as an infusible therapy to target the lung capillary glycocalyx in order 
to mechanically enhance the capillary barrier and turn off pressure-induced 
mechanotransduction.  Copolymers were tested for functional efficacy by 
measuring both albumin permeability (PDA) and hydraulic conductivity (Lp) across  
cultured endothelial monolayers.  P(TMA)Cl significantly decreased PDA in normal  
     
*This chapter is adapted from Giantsos et al. Biomaterials 30:5885-91 (2009) 
with permission from the journal.  
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and inflamed cells and attenuated pressure-induced increases in Lp.  Decreases 
in Lp across endothelial monolayers in the presence of P(TMA)Cl are evidence of 
a dampening of mechanotransduction-induced barrier dysfunction.  This chapter 
outlines preliminary experiments in the development and optimization of 
biomimetic polymers that associate with lung endothelium to be used as a 
therapy to enhance endothelial barrier function and thereby attenuate a major 
component of vascular inflammation. 
 
2.2 Introduction 
The endothelial glycocalyx serves as an interface between blood flow and 
the endothelial cell surface and acts as both a passive barrier between serum 
components and pericapillary tissues and active involvement in the stress-
induced changes to the integrity of the endothelial junction, including release of 
endothelium-derived relaxation factors (68) such as nitric oxide (9, 69) and 
prostacyclin (9), and increases in hydraulic conductivity under increased 
pressure (70).  The mechanism by which cells sense extracellular changes in 
their environment is largely unknown but it is likely a synergistic between the 
perturbation of mechanosensors at the cell surface and distortions experienced 
by the cell that are communicated to the actin cytoskeleton (71).   
The actin cytoskeleton is a dynamic network of filaments and microtubules 
in constant motion. Under conditions of shear stress the displacement of the 
cytoskeleton significantly increases at the luminal surface of the cell (72) where 
extracellular domains of transmembrane protein components of the glycocalyx 
are found.  The role of the glycocalyx in the translation of shear stress and 
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hydrostatic pressure to physiological manifestations has been investigated (8, 9, 
70).  Shear stress increases the production of reactive oxygen species (ROS) in 
endothelial cells (73) and enzymatic removal of key constituents of the 
glycocalyx, such as heparan sulfate, hyaluronan, and sialic acid, abolishes the 
increase of ROS (9).  Increasing the hydrostatic pressure across endothelial cells 
exponentially increases the hydraulic conductivity of fluid through the monolayer; 
removal of heparan sulfate, a major component of the transmembrane 
proteoglycan syndecan, abolishes the increase in hydraulic conductivity (10).  
Taken together, these data suggest that components of the glycocalyx are able 
to sense changes in their environment and translate these changes into signals 
that dictate capillary endothelial function.   
In order to dampen the signaling arising from perturbations of the 
glycocalyx that precipitates changes in the microvasculature, water-soluble 
copolymers are intercalated into the glycocalyx to stiffen the matrix with the aim 
to dampen mechanotransduction.  Cationic copolymers are able to form ionic 
attachments to the glycocalyx, whose net negative charge is attributed to the 
high degree of sulfation and carboxyl moieties that reside on its component 
proteoglycans and glycosaminoglycans (GAGs).  
Cationic copolymers are used ubiquitously in nonviral gene delivery as a 
vehicle in which DNA is packaged through charge-charge interactions and taken 
up into cells (41, 47, 53).  The approach taken here is to use cationic HPMA 
copolymers to interact with the negatively charged endothelial glycocalyx with 
minimal cellular response. 
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The ultimate goal for copolymers targeted to the microvasculature is for 
use in the clinical setting as a treatment for pulmonary edema that occurs during 
cases of acute lung injury or acute respiratory distress syndrome.  In this study, 
we address three fundamental aspects of any therapy: safety, targeting capacity, 
and efficacy.  We demonstrate the safety of P(HPMA) copolymers by noting the 
reduction of lactate dehydrogenase (LDH) release in the presence of quaternary 
ammonium functional groups as opposed to copolymers containing primary 
amine side chains.  We demonstrate polymer attachment to the glycocalyx by 
incubating fluorescently labeled copolymers with endothelial monolayers and 
showing high retention of fluorescent signal after extensive wash steps.  Lastly, 
the efficacy of copolymers is demonstrated in their ability to attenuate both 
albumin diffusion and hydraulic conductivity across endothelial monolayers. 
 
2.3 Materials and methods 
2.3.1 Copolymer synthesis/characterization 
Polymers are synthesized by radical polymerization of N-(2-
hydroxypropyl)methacrylamide (HPMA) and N-(3-aminopropyl)methacrylamide 
(MA-AP) or methacrylamidopropyltrimethylammonium chloride (MA-TMA Cl) 
monomers in two feed ratios using methanol as the solvent with 2,2-
azobisisobutryonitrile (AIBN) as the initiator. The concentration of comonomers in 
the polymerization mixture was 12.5 wt% and the AIBN concentration was 0.6 
wt%. For fluorescence studies, 1 mol% 5-3-(methacryloylaminoropyl)thioureidyl 
fluorescein (MA-FITC)  was added to the polymerization mixture.  Radical 
polymerization was allowed to proceed under nitrogen atmosphere at 55°C for 24 
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hours.  Molecular weight and molecular distribution were determined by size 
exclusion chromatography using an AKTA FPLC equipped with UV and RI 
detectors and a Superose 6 column in tetramethylammonium chloride (TMAC) 
buffer (0.25 M CH3COONa, 0.5 M NaCl, 0.03 M TMAC, pH 6.0).  The quaternary 
ammonium content was determined by the titration of the chloride counterion 
using AgNO3 (74) and fluorescein as the indicator. The primary amine content 
was determined by ninhydrin assay (75).  Both assays were performed in 
triplicate and are presented in Table 2.1 as mean ± standard deviation.   
 
2.3.2 Cytotoxicity 
 The release of lactate dehydrogenase (LDH) was evaluated using a 
commercially available bioassay kit (BioVision, Mountain View, CA).  A cell 
suspension (1.5 x 104 cells/well) of bovine lung microvascular endothelial cells 
(BLMVEC) was added to a microtiter plate and incubated at 37°C for 30 minutes 
with increasing concentrations of 40P(TMA)Cl or 40P(AP). Postincubation, cells 
were centrifuged at 250 x g and the supernatant was added to the reaction 
solution containing a tetrazolium salt that is cleaved to colored formazan in the 
presence of LDH.  After reacting at room temperature for 30 minutes, 
absorbance was evaluated on a GENious 96-well plate reader (Tecan, Durham, 
NC) at 492 nm.  The cytotoxicity is calculated according to equation 2.1. 
 
! 
Cytotoxicity(%) = (sample "CL )(CH "CL )






Table 2.1.  
 
Copolymer characterization data. 
 
                   
No. Name   Structure of   Feed   Polymer  Molecular  %  
    side chain   composition  composition  weightc  Yield 
        (mol%)  (mol %)  (kDa) (PDI)    
1 40P(AP)  -NH(CH2)3-NH2  40   35a   ND   66% 
2 80P(AP)  -NH(CH2)3-NH2  80   70a   ND   81% 
3 40P(TMA)Cl  -NH(CH2)3N(CH3)3+Cl- 40   46b   53.8 (1.8)  72% 
4 80P(TMA)Cl  -NH(CH2)3N(CH3)3+Cl- 80   70b   65.6 (2.1)  79%  
Notation used in Table 2.1: ND: not determined. aDetermined by ninhydrin test. bDetermined by titration with AgNO3.  
cDetermined by size exclusion chromatography. Fluorescent copolymers were polymerized with 1 mol% MA-FITC in feed 




CL represents low control cells receiving no treatment and CH represents high 
control cells receiving 1% Triton X-100.  Statistics are calculated using n = 3 
replicates per group. 
 
2.3.3 Copolymer/cell interactions 
BLMVEC were subcultured on glass coverslips pretreated with 0.4% 
gelatin for 1 hour and 100 !g/mL fibronectin for 1 hour and cultured to 
confluence.  Cells were rinsed with PBS (pH 7.4) then incubated for 30 minutes 
at 37ºC with 40P(FITC)TMA Cl at a concentration of 1 mg/mL in phenol red-free 
DMEM supplemented with 1% BSA, 25 mM HEPES at pH 7.4.  Cells were 
subsequently washed in PBS and fixed for 10 minutes in 2% paraformaldehyde 
at room temperature.  Monolayers were rinsed in PBS then incubated at room 
temperature with 0.1% Triton X-100 to permeabilize cell membranes.  Phalloidin 
conjugated with AlexaFluor 660 (Invitrogen) was dissolved in methanol (6.6 !M), 
diluted to 0.165 !M in PBS, and 200 !L was added to each glass-mounted cell 
monolayer.  Incubation time was 40 minutes at 37ºC then cells were washed in 
PBS and mounted onto slides using ProLong Gold Antifade reagent to mitigate 
photobleaching of the far-red dye.  Slides were imaged on an Olympus FV1000-
xy confocal microscope at 40x magnification in 0.1 !m sections at excitation 
wavelength of 663 and emission wavelength of 690 in channel 1 and ex/em 
494/521 in channel 2.  Sections were rendered in 3D using Volocity software 





2.3.4 Albumin diffusion 
BLMVEC were subcultured on Costar Transwell polycarbonate 
membranes with a 0.4 !m pore size and a growth area of 1.12 cm2 at a density 
of 2.5 x 105 cells/cm2.  Before seeding, the filters were treated with bovine gelatin 
and fibronectin and experiments were performed 7-10 days after plating.  On the 
day of the experiment, warm test media, which is composed of HEPES (25 mM), 
penicillin/streptomycin (0.01%), and bovine serum albumin (BSA, 1%) in MCDB-
131 (11.6 g/L) at pH 7.4, hereby denoted as Media II or MII, is added to a custom 
block chamber designed to hold Transwell chambers.  Cell media containing 1% 
tetramethylrhodamine-conjugated BSA (TMR-BSA) in place of bovine serum 
albumin is added to the abluminal chamber of the Transwell directly onto 
BLMVEC monolayers, with or without polymer solution, to create a final volume 
of 0.5 mL and TMR-BSA concentration of 0.5 mg/mL.  The abluminal chamber is 
sampled once per hour, replacing media, and signal from the TMR-BSA is 
detected on a microplate reader at ex/em 541/572 nm.  The permeability 





A # t # Lconc
     (2.2) 
 
 
PDA is the diffusive permeability coefficient in cm/s, !C is the change in tracer 
concentration in the abluminal chamber, Avol is the abluminal chamber volume in 
mL, A is the monolayer surface area (cm2), t is time in seconds, and Lconc is the 
luminal concentration of tracer in mg/mL.  Post-experimentation, cells are fixed in 
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formalin and stained with Ladd Multiple Stain to ensure confluent and intact 
monolayers. The experiment was performed in triplicate. 
 
2.3.5 Hydraulic conductivity measurements 
 Snapwell filters housing confluent monolayers of BLMVEC were 
inserted into custom permeability chambers, which were custom built from two 
solid polycarbonate cylinders.  The bottom half contains a small pressure-
equilibrated reservoir (abluminal) that houses a Snapwell filter and seals with a 
rubber O-ring.  The top half of the chamber contains a concavity that provides a 1 
mL reservoir above the filters; it seals against the top rim of the Snapwell with a 
second O-ring.  Two spring-loaded latches on the outside of the chamber lock 
the two halves of the cylinder together to form a watertight housing for the cells 
and their supports.  The top of the permeability chamber has two stopcock-
controlled ports for inflow and outflow of tissue culture media. A combination 
camera stand and glass capillary tube holder is custom built as one tightly fitted 
structure and machined from heavy aluminum.  This design allows the camera to 
be calibrated only once for multiple uses of the equipment.  The camera is a 
Sony RS-170 monochromatic video camera and programming of the video 
tracking and analysis software was done using LabVIEW (National Instruments, 
Austin, TX).  The pressure manifold is composed of repurposed disposable 
polystyrene serological pipettes connected to a 5-stopcock manifold.  Silastic 
tubing connects the inflow port of the permeability chamber with the pressure 
manifold.  The portion of the silastic tubing that runs beneath the camera and 
houses the air bubble is fitted with an 18 cm length of clear borosilicate capillary 
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tubing with an internal diameter of 1.9913 mm ± 0.0004.   
A schematic for the experiment process is given in Figure 2.1.  During an Lp 
experiment, cell monolayers were placed in the chambers with MII and allowed to 
equilibrate for 1 hour under a hydrostatic pressure of 1 cm H2O.  After 1 hour, the 
pressure was increased to 10 cm H2O.  Following another hour, either a 1 mg/mL 
solution of 40P(TMA)Cl, P(HPMA), or MII only, denoted as control, was applied 
to the chamber housing BLMVEC monolayers.  After 30 minutes, cells treated 
with polymer were washed with MII and monitored for another hour.  Water 
pressure was increased by 5 cm H2O every hour and Lp data were constitutively 
collected every 5 seconds. Postexperiment, Snapwell chambers were fixed in 
formalin and stained with Ladd Multiple Stain to ensure confluence.  All 
monolayers included in data analysis were confirmed to be 100% confluent at the 




 Data are expressed as means ± standard deviation with differences 
between groups assessed using nonparametric Dunn’s test to show differences 
between three or more groups with unequal variances or paired t-tests when 
evaluating data between pressure increases.  Graphics were generated in 



































2.4.1 Copolymer synthesis/characterization 
 Copolymers of HPMA and primary amine or quaternary ammonium 
cationic groups were synthesized for side-by-side comparison (Figure 2.2).  For 
either copolymers of HPMA and trimethylammonium chloride (TMA Cl) or primary 
amine side chains (AP), two charge densities were obtained, either 
approximately 40 or 80 mol% cation composition (Table 2.1).  Precise 
assessment of the final copolymer content of cationic residues results in values 
5-10% lower than the feed ratios, in accordance with expectation and probability 
of polymerization.  The molecular weights and polydispersity indices were similar  
for 40P(TMA)Cl and 80P(TMA)Cl and were obtained only for quaternary 
ammonium copolymers since these copolymers were the primary focus of 
binding and functional studies. 
 
2.4.2 Cytotoxicity 
 The cytotoxicity of copolymers was evaluated by monitoring the release of 
LDH from cultured microvascular endothelial cells.   LDH release was minimal in 
groups treated with P(HPMA) or P(TMA)Cl; only at the highest concentration of 
polymer and highest mol% of TMA [80P(TMA)Cl at 10 mg/mL] does the 
cytotoxicity exceed 10% (Figure 2.3 A).  At the same concentration and 
composition percent, primary amine comonomers elicit 5- to 6-fold increases in 
LDH release (Figure 2.3 B).  Marked cytotoxicity occurs in the presence of 




Figure 2.2. Polymer structures of (A) P(AP) and (B) P(TMA)Cl 
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cationic polymers behave similarly.  Copolymers possessing quaternary 
ammonium groups exhibit significantly less cytotoxicity than copolymers 
composed of primary amine groups at higher feed compositions and are 
therefore chosen for further studies. 
 
2.4.3 Copolymer-cell interactions 
We show that positively charged copolymers can interact with the 
endothelial glycocalyx (Figures 2.4 A and 2.4 B).   Fluorescently labeled 
40P(FITC)TMA Cl is shown as the green layer on the top of the cells and the 




Figure 2.3. Cytotoxicity of copolymers as ascertained through LDH release for 
(A) P(TMA)Cl and (B) P(AP) of increasing concentrations.  Copolymers 
containing primary amines showed significant cytotoxicity at higher mol% 
composition and higher concentrations whereas the cytotoxicity of quaternary 
ammonium copolymers exceeded 10% only at maximal charge mol% 




Figure 2.4. Confocal images of surface-bound 40P(FITC)TMA Cl (46) and actin 
cytoskeleton (red) as seen at (A) 45° and (B) 90° to the z axis.  Figure 
incorporates approximately 75 cells imaged at 40x magnification.  
40P(FITC)TMA Cl covers the monolayer after vigorous rinsing steps and actin 
staining demarcates the cell membrane from the cytoplasmic compartment.   
 
 
visible between the extracellular polymer and the internal actin cytoskeleton 
(Figure 2.4 B) demonstrating that the polymer is able to interact with the 
glycocalyx at the cell surface. 
 
2.4.4 Albumin diffusion 
 Endothelial monolayers treated with 5 and 10 mg/mL concentrations of 
40P(TMA)Cl demonstrated a significant reduction in the permeability coefficient 
compared to control monolayers receiving no treatment (Figure 2.5 A).  When 
P(HPMA) was used in place of 40P(TMA)Cl, no statistical difference was seen 
among any of the groups (Figure 2.5 B).   
To test the potential of polymers to decrease PDA under inflammatory 
conditions, endothelial monolayers were exposed to the inflammatory agonist 
bradykinin (1 !M) during experimentation.  The addition of bradykinin to cells 
increased the albumin permeability coefficient by nearly 2-fold after 1 hour 




Figure 2.5 Permeability coefficients of albumin diffusion across confluent 
BLMVEC in the presence of (A) 40P(TMA)Cl or (B) P(HPMA).  40P(TMA)Cl 
reduces PDA in a concentration-dependent manner consistent with quantitative 
binding to the glycocalyx and enhancement of passive barrier function.  P(HPMA) 
was unable to significantly reduce PDA with respect to control at any 





Figure 2.6  Albumin diffusion coefficients of cell monolayers treated with cytokine 
and/or 40P(TMA)Cl.  Addition of bradykinin (BK, grey bar) to monolayers 
increases permeability coefficient.  Concurrent addition of 40P(TMA)Cl (shaded 
bar) abolishes the bradykinin-induced increase in PDA compared to control 
diffusion coefficients (black bar).  *P < 0.05; Nonparametric Dunn’s test, N=3 
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bradykinin and 40P(TMA)Cl, the permeability coefficient was reduced to that of 
control cells receiving neither polymer nor bradykinin. 
 
2.4.5 Hydraulic conductivity of endothelial monolayers 
 Copolymer solutions were applied to cell monolayers prior to Lp 
experimentation.  A schematic for the experiment protocol is given in Figure 2.1.  
Lp values were normalized to the average of the Lp values acquired during the 
last 5 minutes of the 10 cm H2O pressure interval in order to facilitate comparison 
between experiments.  Peak normalized Lp values are the average of the Lp 
values acquired during the last 5 minutes of a given interval.  Figure 2.7 
compares cells receiving no polymer treatment to those receiving 40P(TMA)Cl 
and P(HPMA) at a concentration of 1 mg/mL.  Treatment with 40P(TMA)Cl 
decreased Lp by 76% compared to controls after cells had been subjected to 
pressures of 20 cm H2O.  Increasing the polymer concentration by ten fold further 
reduced Lp by 20% but when compared to controls, percent Lp reduction was 
76% and 81% for concentrations of 1 mg/mL and 10 mg/mL, respectively (data 
not shown).  These figures show compelling evidence for the ability of polymers 
to enhance the function of the glycocalyx by reducing hydraulic conductivity 
across endothelial monolayers. 
 
2.5 Discussion 
 The ultimate goal for copolymers targeted to the microvasculature is for 
use in the clinical setting as a treatment for pulmonary edema.  This study 




Figure 2.7. Hydraulic conductivity measurements taken from control cells (stripe) 
and cells treated with P(HPMA) (black) or 40P(TMA)Cl (shaded).  40P(TMA)Cl 
significantly reduced peak normalized Lp at 20 cm H2O pressure.  *P < 0.05; 
Dunn’s nonparametric test, N = 5-7.  
 
and efficacy. The safety of HPMA-based copolymers is demonstrated by noting 
the reduction of LDH release in the presence of quaternary ammonium functional 
groups as opposed to copolymers containing primary amine side chains.  
Confocal experiments demonstrate the capacity for cationic copolymers to form 
strong associations with the glycocalyx.  Lastly, the efficacy of copolymers is 
demonstrated in their ability to attenuate both albumin diffusion and hydraulic 
conductivity across endothelial monolayers. 
Cationic copolymers were synthesized to contain increasing molar ratios 
of primary amine and quaternary ammonium conjugates in order to maximize 
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binding to the glycocalyx while minimizing cell uptake.  Initial cytotoxicity 
experiments suggested that primary amine copolymers and 80P(TMA)Cl would 
elicit an undesirable cellular response so the characterization of molecular 
weights and averages of copolymers was restricted to the copolymers to be used 
in further studies, namely 20P(TMA)Cl and 40P(TMA)Cl.  Cellular response was 
measured using an LDH release assay; lactate dehydrogenase is released from 
cells prior to apoptosis and is therefore a standard marker for cell death.  
Consistent with previous studies quantifying transfection efficiency for gene 
delivery purposes (53), we also saw that copolymers composed of primary 
amines elicited a greater cellular response than did those composed of 
quaternary ammonium.  It has been shown in studies that evaluate cationic 
copolymers for gene delivery that copolymers that carry quaternary ammonium 
charges tend to elicit less cytotoxicity and have a lower transfection activity than 
copolymers composed of primary amines in cellular systems (53).  As P(HPMA) 
itself elicits negligible immunogenic response (44, 45), it would be expected that 
copolymers with greater cationic charge density should elicit the greater 
cytotoxicity response in serum-free media.   
The capacity of 40P(TMA)Cl to bind to the negatively charged glycocalyx 
was demonstrated using confocal microscopy.  Fluorescently labeled 
40P(FITC)TMA Cl was incubated with confluent endothelial monolayers and 
washed extensively from the cell surface before imaging.  Copolymer is 
visualized in green and the actin cytoskeleton in red.  The staining pattern of the 
copolymer is consistent with reports of heterogeneity of the glycocalyx across the 
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capillary (76).  The staining of submembrane actin served to distinguish the 
cytoplasmic compartment from the cell surface.  A clear line of delineation 
between the cell surface and cytoplasm is visible, suggesting that the polymer 
remains on the exterior of the cell.  
In functional assays, the diffusion of labeled albumin across confluent 
monolayers is a model for protein extravasation through the endothelial barrier 
and serves as a measure of barrier integrity.  When 40P(TMA)Cl was added to 
monolayers, the permeability coefficient decreased with increasing polymer 
concentration and reached significant levels of difference at concentrations of 5 
and 10 mg/mL.  No such trend was seen with P(HPMA).  Since there is no 
pressure upon the cell monolayer to force copolymer into the glycocalyx, 
P(HPMA) has no effect on PDA thus it is clear that ionic contacts are necessary to 
bring the copolymer into contact with the cell surface to reduce protein flux from 
the apical to basal sides of the cell monolayers.   
To test the efficacy of cationic copolymer on enhancing barrier function in 
the course of inflammatory states, the inflammatory agonist bradykinin was 
added to cell chambers and PDA increased dramatically after 1 hour.  Concurrent 
addition of 40P(TMA)Cl to monolayers subjected to bradykinin treatment reduced 
PDA to levels similar to those of controls.  This is likely due to the ability of 
40P(TMA)Cl to intercalate into the glycocalyx and block serum proteins from 
moving from one side of the barrier to the other, thus enhancing the passive 
function of the glycocalyx.   
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Previous work has shown the influence of hydrostatic pressure on the flux 
of fluid from the capillary lumen to the surrounding tissue (7, 70).  The 
intercalation of polymer into the glycocalyx is hypothesized to reduce 
mechanotransduction that occurs when glycoproteins on the cell surface 
experience perturbations due to hemodynamic forces.  Biomimetic copolymer 
administration is hypothesized to dampen signaling to the actin cytoskeleton, 
which contacts transmembrane glycoproteins, focal adhesions and adherens 
junctions, all of which regulate fluid flux across the capillary (71).  Dull et al. have 
shown previously that pressure increases across endothelial monolayers 
increase fluid flux from the luminal side of the monolayer to the basolateral side 
and that removal of key components of the glycocalyx abolishes the pressure-
induced increase in hydraulic conductivity (70), thus providing evidence that the 
glycocalyx plays an active role in mechanotransduction.  40P(TMA)Cl was 
removed from the permeability chambers in Lp experiments after an incubation 
period in order to mimic the effect of an infusion and subsequent washout period 
of copolymer delivered to the microvascular capillary lumen.  There was a 
significant decrease in hydraulic conductivity between control cells and those 
treated with solutions of 40P(TMA)Cl.  P(HPMA) alone was also able to reduce 
hydraulic conductivity when compared to controls, which can be attributed to 
incomplete polymer removal from cell monolayers as polymers in a static system 
under pressure will be able to associate with the glycocalyx via van der Waals 
and dipole-dipole interactions.  The decrease in hydraulic conductivity suggests 
polymeric intercalation into the glycocalyx, which can either enhance the passive 
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role of the glycocalyx, potentially by creating a thicker barrier for fluid to pass 
through, and attenuate the active role of mechanotransduction by theoretically 
limiting the motion of cell surface glycoproteins.  
 
2.6 Conclusion 
 The safety, applicability and efficacy of a water-soluble biomimetic 
polymer with potential as a clinical therapy for patients with acute lung injury are 
shown in this work.  Moreover, there is compelling evidence that deformations in 
the endothelial glycocalyx are a major factor in mechanotransduction and that the 
administration of a material capable of limiting such deformations is relevant.  
The clinical implications for a simple yet elegant therapy to counteract the life-
threatening effects of pulmonary edema are significant and further development 















MECHANISM AND EX VIVO STUDIES OF COPOLYMER 
 






 Therapeutic compound(s) capable of attenuating changes in vascular 
barrier function would represent a significant advance in critical care of 
pulmonary edema and the associated increases in vascular permeability that 
continue to represent a significant problem in the clinic. We have previously 
reported the development of HPMA-based copolymers, targeted to endothelial 
glycocalyx that are able to enhance barrier function. In this work, we report the 
refinement of copolymer design and extend our physiological studies to 
demonstrate that the polymers: 1) reduce both shear- stress and pressure-
mediated increase in hydraulic conductivity, 2) reduce nitric oxide production in 
response to elevated hydrostatic pressure and, 3) reduce the capillary filtration 
coefficient (Kfc) in an isolated perfused mouse lung model.  These copolymers  
     
‡The shear-induced hydraulic conductivity measurements (section 3.3.3) were 
performed by Veronica Lopez-Quintero, a graduate student at the City College of 
CUNY under the advisement of Dr. John Tarbell, a close collaborator with Dr. 
Dull.  The polymers used in the experiment were my design and the resulting 
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represent an important tool for use in mechanotransduction research and a novel 
strategy for developing clinically useful copolymers for the treatment of vascular 
permeability. 
      
3.2 Introduction 
 It has been long appreciated that endothelial cells are able to sense 
mechanical forces imparted by flowing blood and respond accordingly. The 
glycocalyx is exposed to shear stress as blood flow distorts surface 
proteoglycans parallel to the capillary wall and increased pressure exerted 
perpendicularly drives flow and shear stress through inter-endothelial junctions 
containing glycocalyx (77); these forces can, in excess, have a deleterious effect 
on the integrity of the capillary barrier.   
 Nitric oxide (NO) is produced in response to shear through calcium 
dependent and calcium independent pathways.  Within seconds after onset of 
shear, transient increases in intracellular calcium activate nitric oxide synthase 
(eNOS) to produce NO (78).  The calcium-independent activation of eNOS by 
laminar shear is a result of phosphorylation of the enzyme (79).  Low levels of 
constitutively expressed NO are responsible for vascular homeostasis in normal 
tissues whereas increased levels of NO are capable of reaction with endogenous 
superoxide to form the powerful oxidant peroxynitrite and thereby instigate barrier 
     
figures and data analysis, along with the remainder of the polymer syntheses and 
experiments in this chapter, are my own.  This chapter is adapted from Giantsos-




dysfunction via deleterious pathways involving reactive oxygen species (80). 
Likewise, it has been shown that the removal of specific components of the 
glycocalyx inhibits this response (8), implicating the endothelial glycocalyx as a 
mechanosensor.  
 The endothelial glycocalyx carries a net negative charge due to sulfate 
and carboxyl groups and sialic acids found on proteoglycans that decorate the 
cell surface and cell junctions.  In vitro studies have shown that the 
administration of a positively charged copolymer that interacts with the negatively 
charged glycocalyx is able to enhance the passive barrier function of the 
glycocalyx and dampen the role of the active barrier regulation component, 
namely mechanotransduction (54). In this work, the net negative charge of the 
endothelial cell surface is exploited to deliver a water-soluble cationic copolymer 
that interacts with the glycocalyx in order to enhance the physical barrier and 
reduce mechanical perturbations to the glycocalyx and thereby attenuate 
mechanotransduction. 
 The goal of these copolymers, clinically, is to lay the foundation for the 
development of a treatment for acute lung injury associated with inflammation 
and altered pulmonary vascular pressures, and to be used in the laboratory as a 
tool toward a better understanding of mechanotransduction pathways.  Some 
work has been done in the realm of therapeutic polymers delivered to lung 
endothelium to treat acute lung injury (81) or as a free radical scavenger (82), 
however, to date the effort is preliminary and the mechanism is largely 
unexplored.  This work explores the relationship between mechanotransduction 
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and polymer molecular weight and charge distribution in order to begin to 
optimize future endeavors in the realm of polymer delivery to enhance barrier 
function.  Here, we show that cationic copolymers possessing low charge density 
are able to reduce shear- and pressure-mediated barrier dysfunction, reduce the 
formation of nitric oxide and reduce the filtration coefficient in an intact lung 
model.  
 
3.3 Materials and methods 
3.3.1 Polymer synthesis/characterization 
 Polymers are synthesized by radical polymerization of HPMA and MA-
TMA Cl monomers in varying feed compositions using methanol as the solvent 
and AIBN as initiator. The concentration of comonomers in polymerization 
mixture was 12.5 wt% and the AIBN concentration was 0.6 wt% or 0.2 wt% for 
20P(TMA)Cl or 10P(TMA)Cl, respectively.  Radical polymerization was allowed 
to proceed under nitrogen atmosphere at 55°C for 24 hours. Molecular weight 
and molecular distribution were determined using AKTA FPLC (GE Healthcare, 
Piscataway, NJ) equipped with UV and RI detectors using a Superose 6 column 
in tetramethylammonium chloride (TMAC) buffer (0.25 M CH3COONa, 0.5 M 
NaCl, 0.03 M TMAC, pH 6.0).  A Superose 6 preparative column under the same 
conditions was used in conjunction with this system for polymer fractionation. 
Quaternary ammonium content was determined by titration of chloride counterion 
using 0.01M AgNO3 (74). Titrations were performed in triplicate with a custom 1 




3.3.2 Cell Culture 
 Bovine aortic endothelial cells (BAEC) and rat lung microvascular 
endothelial cells (RLMVEC) were purchased from Vec Technologies 
(Rensselaer, NY) and grown in T-75 flasks with 10% FBS in complete medium, 
purchased from Vec Technologies, at 37°C in 5% CO2.  Upon reaching 
confluence (3-4 days) the cells were split for continuing maintenance of the cell 
line.  BAEC were plated at a density of 1.25 x 105 cells/cm2 on polycarbonate 
Transwells previously coated with 1% fibronectin. RLMVEC were plated on 1% 
fibronectin and 0.05% gelatin or 10% FBS-MEM for Snapwells or Transwells, 
respectively, and incubated in 5% CO2 at 37°C. The shear-permeability 
experiments were run 4-6 days after plating and pressure-permeability 
experiments were run on days 9 and 10 after plating. Cells were used from 
passages 4 to 7. 
 
3.3.3 Shear-induced hydraulic conductivity (Lp) 
 Prior to Lp measurements, BAEC were cultured on Transwell membrane 
supports (12 mm diameter, 0.4 !m pore size) and grown to confluence.  On the 
day of the experiment, monolayers were incubated with either 20P(TMA)Cl (70.2 
kD, PD 1.8), 20P(TMA)-F3 (135 kD, 1.1 PD), or 20P(TMA)-F5 (24 kD, PD 1.2) at 
a concentration of 1 mg/mL in 1% BSA for 30 minutes at 37°C and then were 
rinsed twice with experimental media (MEM supplemented with 1% BSA) and 
placed in the transport apparatus to determine shear-induced hydraulic 
conductivity  as previously described (83).  The measurement of fluid flow across 
the endothelial monolayer was performed inside a Plexiglas box maintained at 
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37°C. The seeded filters were placed inside a chamber to form a luminal (top) 
compartment and an abluminal (bottom) compartment separated only by the 
BAEC monolayer. The abluminal compartment was connected to a reservoir via 
Tygon and borosilicate glass tubing. The vertical displacement of the reservoir 
with respect to the liquid covering the cells applied a hydrostatic pressure 
differential across the monolayer. At 10 cm H2O differential pressure, the 
volumetric flow rate (Jv) was measured by tracking the position of an air bubble 
that was placed into the calibrated borosilicate glass tube. The hydraulic 





"P      (3.1) 
 
A represents the area of the BAEC monolayer and !P is the pressure differential 
across the monolayer. During each experiment, one untreated endothelial 
monolayer was tested as control while a copolymer solution was applied to a 
separate monolayer and both experiments were run concurrently.  After 60 
minutes of applied pressure differential, a baseline Lp was established for each 
respective monolayer and a defined shear stress was applied to each endothelial 
monolayer. Lp values were collected for 4 hours.  Shear was applied to the 
surface using a rotating disk separated by a distance h (500 "m) from the 
monolayer surface. The rotating disk generated a fluid shear stress distribution 







h       (3.2) 
       
The variable µ represents the viscosity of the media, ! is the rotational speed, 
and r is the radial distance from the center of the disk. The parameters were 
adjusted in order to achieve a maximum steady shear stress of 20 dyn/cm2 at the 
edge of the disk. The average shear stress over the entire filter area is 2/3 of the 
maximum. The luminal compartment and the reservoir were supplied with 5% 
CO2 throughout the experiment to maintain the media at pH 7.4.  
 
3.3.4 Pressure-induced hydraulic conductivity 
 The system used to measure the volumetric flux rate (Jv) and hydraulic 
conductivity (Lp) has been described previously (84) and also thoroughly in 
section 2.3.5. RLMVEC monolayers were allowed to equilibrate for 1 hour under 
a hydrostatic pressure of 1 cm H2O in PRF-MII (phenol red-free DMEM with 25 
mM HEPES, 1% BSA, and 0.01% penicillin/streptomycin at pH 7.4).  For 
experiments involving L-NAME (N!-nitro-L-arginine methyl ester hydrochloride), 
cells were incubated at 37ºC for 1 hour prior to experiment with 10 "M L-NAME 
and the NO blocker was present in media for the duration of the experiment.  For 
polymer-treated experimental groups, after the 1 hour equilibration period, a 
solution of 20P(TMA)Cl (1 mg/mL) in PRF MII was added to the luminal cell 
chamber and the pressure was increased to 10 cm H2O. After 30 minutes, 
polymer was washed from cells with a 6-fold volume of PRF MII and the 
experiment was allowed to proceed under 10 cm H2O pressure for another half 
hour.  The water pressure was subsequently increased by 10 cm H2O every 
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hour; Lp data were constitutively collected every 5 seconds.  At the end of the 
experiment, Snapwells were removed from permeability chambers and 
monolayers were fixed in formalin and stained with Ladd Multiple Stain (Ladd 
Research, Williston, VT) to confirm monolayer integrity.  An aliquot (500 !L) of 
the media above the cells was collected, centrifuged and frozen for NO analysis.  
 
3.3.5 Nitric oxide detection 
 The nitric oxide content was evaluated using an NO Quantification Kit 
(Active Motif, Carlsbad, CA). Nitrates in the sample were reduced to nitrites using 
nitrate reductase and the Greiss reaction was utilized to colorimetrically quantify 
the products of NO in the supernatant samples.  Assays were performed in 
triplicate and evaluated using a microplate reader (Tecan, Mannedorf, 
Switzerland) at absorbance wavelength 540 nm with reference wavelength 612 
nm. 
 
3.3.6 Ex vivo lung preparation   
 All animal experiments were approved by the University of Utah’s 
Institutional Animal Care and Use Committee (IACUC) and are in accordance 
with the Guide for the Care and Use of Laboratory Animals (National Research 
Council).  C57/BL6 mice (20-25 grams) were anesthetized with 
ketamine/xylazine (80/10 mg/kg), a tracheotomy was performed and they were 
mechanically ventilated with a pressure-controlled ventilator (Kent Scientific, 
Torrington, CT). Respiratory rate was 50/minute, and peak inspiratory pressure 
(23) was 7-10 cm H2O. The chest and pericardial sac were sequentially opened 
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and ligatures were placed around the aorta and pulmonary artery. Heparin (200 
U) was injected into the pulmonary artery and allowed to circulate for 2 minutes. 
The mouse was exsanguinated via a left ventriculostomy and the left atrium was 
cannulated via the left ventriculostomy. The pulmonary artery was cannulated via 
the right ventricle and lungs were perfused with Krebs-Ringers-bicarbonate 
solution (Sigma Chemical, St. Louis, MO) containing 3% bovine serum albumin 
(BSA; Fraction V, Proliant, Ankeny, IA).  Pulmonary artery  (PPA) and left atrial 
pressures (85) were measured continuously via in-line pressure transducers (P-
75, Harvard Apparatus, Natick, MA) connected to an A/D board. Solenoids 
(20PSI, 12V DC, Cole Parmer, Mount Vernon, IL) were placed in-line on both the 
arterial and venous tubing and could be closed simultaneously for measuring 
double occlusion pressures (PDO). An in-line ultrasonic flow probe (Transonic, 
Ithaca, NY) was placed in the pulmonary artery cannula and flow data was 
recorded in real-time. Lungs were suspended from a force transducer (Radnoti, 
Minrovia, CA) and lung weight was zeroed; lung weight, vascular pressures and 
flow were recorded using a custom-written program (Labview, National 
Instruments, Austin, TX).  An experiment scheme is presented in Figure 3.1. 
 
3.3.7 Calculation of Kfc 
 Lungs were perfused at 2 ml/min, left atrial pressure = 2 cm H2O during a 
20 minute isogravimetric period. To measure Kfc, PLA was increased to 7 cm H2O 
for 20 minutes and the slope of weight gain/time during 18-20 minutes was used 





Figure 3.1. Schematic of an isolated perfused lung experiment.  Pressure (bottom plot) is the independent variable and 








           (3.3) 
 
The relationship !wt/t is the slope of the line depicting weight gain over time and 
Pc is the capillary pressure calculated according to equation 3.4. 
! 
Pc = PPA +
PLA
2     (3.4) 
Units are in mL/min/cm H2O, PPA represents pulmonary artery pressure and PLA 
represents left atrial pressure.  This value was normalized to 100 grams of 
predicted lung weight.  After the 20 minute increase in PLA, the pressure is 
reduced to 2.0 cm H2O for 20 minutes and the polymer was perfused into the 
lungs via the pulmonary artery catheter at a rate of 1 mg/mL/min. PLA was then 
increased to 7 cm H2O and Kfc was measured from 18-20 minutes. The ratio of 
Kfc2/Kfc1 was used to assess the effect of polymers on whole lung permeability. 
 
3.3.8 Statistical analysis 
 Lp values are presented as mean ± standard deviation. A P-value less 
than 0.05 is considered significant. Statistics were performed with ANOVA and 
Tukey’s post hoc comparison where appropriate.  All other statistical tests are 
specified in the figure caption. 
 
3.4 Results 
3.4.1 Copolymer synthesis and characterization 
 Copolymers of HPMA and MA-TMA Cl were synthesized in two feed ratios 
to create polymers of either 10 or 20 mol% quaternary ammonium content. Table 








Copolymer characterization data 
 
                   
 
Name   Feed composition Polymer composition  Molecular weight  Charges per 
   (mol %)  [mol % (SD)]    [kDa (PDI)]   macromolecule  
20P(TMA)Cl  20   19.9 (1.4)    70.2 (1.8)*   95 
20P(TMA)Cl-F3 20   19.9 (1.4)    135 (1.1)   182  
20P(TMA)Cl-F5 20   19.9 (1.4)    24 (1.2)   32 
10P(TMA)Cl-F2 10   10.7 (0.7)    90 (1.2)   65 
PEO   ---   ---     82 (1.1)   --    
 
Polymer nomenclature and characterization data.  Approximate percent composition of TMA Cl is denoted as the number, 







and Figure 3.2 shows the molecular structure for TMA-HPMA copolymers.  The 
unfractionated molecular weight of 10P(TMA)Cl (Mw 135 kD, 1.9 PD) was higher 
than that of 20P(TMA)Cl (70.2 kD, PD 1.8) because of the lower AIBN 
concentration in the polymerization reaction mixture.  10P(TMA)Cl and a portion 
of 20P(TMA)Cl were fractionated.  The molecular weight profile for unfractionated 
20P(TMA)Cl and fractionated 20P(TMA)Cl-F3 and 20P(TMA)Cl-F5 are given in 
Figures 3.3, 3.4, and 3.5, respectively. Fractionation resulted in narrow molecular 
weight distributions.  The exact concentration of quaternary ammonium charges 
per mole of polymer was found to be within 1% of the theoretical value.  These 
values were then used to calculate the charges per macromolecule of polymer to 




Figure 3.2. Structure of a P(TMA)Cl copolymer.  All copolymers used in this 
study possess this basic structure.  Alterations are made in percent composition 














Figure 3.3. Molecular weight profile for unfractionated 20P(TMA)Cl copolymer.  Profiles are generated using AKTA 
software and a Superose 6 column in tetramethylammonium chloride (TMAC) buffer (0.25 M CH3COONa, 0.5 M NaCl, 

















 Peak 1 
Peak limits (min)  22.862 - 36.192 
dn/dc (mL/g)   0.170 
Polydispersity 
  Mw/Mn   1.072(0.2%) 
  Mz/Mn   1.157(0.4%) 
Molar mass moments (g/mol) 
  Mn   1.260e+5(0.1%) 
  Mp   1.258e+5(0.1%) 
  Mv   n/a 
  Mw   1.351e+5(0.2%) 
  Mz   1.458e+5(0.4%) 
 
 
Figure 3.4. Size exclusion profile and characterization data for 20P(TMA)Cl-F3. 
The blue trace is refractive index (RI) and the red trace is light scattering (LS) 
data.  Profiles are generated using AKTA instrumentation, ASTRA MiniDawn 
software, and a Superose 6 column in tetramethylammonium chloride (TMAC) 













 Peak 1 
Peak limits (min)  34.796 - 47.301 












Figure 3.5. Size exclusion profile and characterization data for 20P(TMA)Cl-F5. 
The blue trace is refractive index (RI) and the red trace is light scattering (LS) 
data.  Profiles are generated using AKTA instrumentation, ASTRA MiniDawn 
software, and a Superose 6 column in tetramethylammonium chloride (TMAC) 










  Mw/Mn   1.151(0.6%) 
  Mz/Mn   1.294(0.9%) 
Molar mass moments (g/mol) 
  Mn   2.089e+4(0.5%) 
  Mp   2.271e+4(0.4%) 
  Mv   n/a 
  Mw   2.403e+4(0.3%) 




3.4.2 Shear induced hydraulic conductivity 
 When BAEC monolayers were compared to controls receiving no polymer 
solution that were run side-by-side with polymer groups, all monolayers treated 
with 20P(TMA)Cl had significantly decreased hydraulic conductivity responses to 
shear.  In Figure 3.6, this is represented as the data points collected in the last 5 
minutes of every hour of the experiment.  The first hour is excluded as this is an 
equilibration period and polymer solution was not added until after the first 60 
minutes. In order to test whether the molecular weight of the polymer would have 
an effect on the degree to which the polymer reduced the cellular response to 
shear, a polydisperse polymer (20P(TMA)Cl, Figure 3.6 A), and both a high- and 
low-molecular weight fraction of a polymer with similar charge density 
(20P(TMA)Cl-F3, Figure 3.6 B and 20P(TMA)Cl-F5, Figure 3.6 C, respectively) 
were tested.  All variations of the polymer significantly reduced shear-induced 
hydraulic conductivity.  The polymer data were normalized to represent percent 
decrease from respective control Lp data (Figure 3.7) according to equation 3.5. 
 
! 
M = [control(t)]" [polymer(t)][control(t)]"1     (3.5) 
    
Control(t) is the value of the normalized Jv/A response without polymer at time t, 
and polymer(t) is the value of the normalized Jv/A response in the presence of 
polymer at time t and 1 represents the baseline value that is obtained in the 
absence of shear stress.  As defined, the higher the value of M, the greater 
suppression of mechanotransduction since greater differences between control(t) 









Figure 3.6. Normalized Lp values of control and polymer-treated monolayers.  
BAEC monolayers were incubated for 30 minutes with 1 mg/mL of A) 
20P(TMA)Cl (dark grey bars), B) 20P(TMA)Cl-F3 (medium grey bars), or C) 
20P(TMA)Cl-F5 (light grey bars). All monolayers pre-incubated with polymer 
display a 50-75% decrease in Lp response to shear compared to control 












Figure 3.7. Shear-induced hydraulic conductivity of monolayers treated with 
20P(TMA)Cl (dark grey bars), 20P(TMA)-F3 (medium grey bars), or 20P(TMA)-
F5 (light grey bars) and normalized to their respective controls.  Normalized 
values for 20P(TMA)Cl-F3 are significantly higher than for other groups indicating 
a greater reduction in shear-mediated hydraulic conductivity with high molecular 
weight copolymers.  * P < 0.05 difference from 20P(TMA)Cl. # P < 0.05 








20P(TMA)Cl-F3 demonstrate a significantly higher value for M than do 
monolayers preincubated with either 20P(TMA)Cl or 20P(TMA)Cl-F5.  We are 
able to show with these data that cationic copolymer incubation protects the 
endothelium against shear-induced increases in hydraulic conductivity and that 
this protective effect augmented in the presence of a narrowly distributed high 
molecular weight copolymer. 
 
3.4.3 Pressure-induced hydraulic conductivity 
 Previously, we reported a decrease in pressure-induced hydraulic 
conductivity using 40P(TMA)Cl, a cationic copolymer composed of approximately 
40 mol% positive charges per macromolecule (54).  Figure 3.8 A shows that a 
further reduction of the charge density to approximately 20 mol% significantly 
lowers the pressure-induced hydraulic conductivity of cell monolayers in 
response to 30 cm H2O fluid pressure.  The administration of L-NAME, an 
inhibitor of nitric oxide synthase (NOS), is also able to significantly reduce the 
hydraulic conductivity from control cells receiving no treatment.  We found no 
significant difference between cell monolayers treated with L-NAME and 
monolayers transiently incubated with a 1 mg/mL dose of 20P(TMA)Cl.  It is 
shown here that the administration of a copolymer that interacts with the 
endothelial glycocalyx reduces the fluid conductance of the cell monolayer in 
response to hydrostatic pressure to a similar degree as monolayers whose 









Figure 3.8. Peak normalized Lp values and nitrate concentration in cell media 
above tested monolayers.  A) Peak normalized pressure-induced hydraulic 
conductivity values obtained after 30 minutes of 30 cm H2O pressure.  Addition of 
20P(TMA)Cl and L-NAME, respectively, significantly decreased the pressure-
induced increase in hydraulic conductivity through monolayers.  No statistical 
difference exists between polymer treated and nitric oxide inhibited monolayers. * 
P ! 0.05, ANOVA/Tukey’s post hoc. N = 8 per group. B) Nitrate concentration of 
media above monolayers exposed to pressure of 30 cm H2O for 60 minutes.  
Incubation with polymer significantly reduces the nitric oxide concentration to that 
of cells incubated with the NO inhibitor L-NAME indicating an intracellular 
mechanism for barrier dysfunction attenuation.  *P < 0.01, N = 8 per group. 
 
3.4.4 Nitric oxide production in response  
to hydrostatic pressure 
 To determine whether the barrier-enhancing effect of polymer 
administration was a consequence of a simple physical barrier enhancement or 
whether polymer administration altered mechanotransduction pathways, the 
media directly above cell monolayers that were exposed to high pressures in 
hydraulic conductivity experiments (outlined in section 3.4.3) was sampled and 




and rapidly produces both nitrate and nitrite as end products, the supernatant 
was incubated with nitrate reductase and the resulting nitrite was assayed 
according to Greiss reaction protocol.  The concentration of nitric oxide products 
in cell supernatant is reported in Figure 3.8 B.  The administration of either L-
NAME (10 !M) or 20P(TMA)Cl (1 mg/mL) copolymer significantly reduced the 
nitric oxide production of cell monolayers when compared to control.  There was 
no significant difference between groups treated with either L-NAME or 
copolymer, therefore, one may conclude that 20P(TMA)Cl attenuates nitric oxide 
production via an intercellular mechanism and that the polymer-assisted 
attenuation of mechanotransduction is not solely the enhancement of a physical 
barrier alone. 
 
3.4.5 Isolated perfused lung preparation 
 To test the therapeutic benefit of copolymers in a whole-organ system, we 
exposed isolated perfused mouse lungs to increased left atrial pressures and a 
subsequent infusion of polymer solutions, either 10P(TMA)Cl or PEO (Figure 3.9) 
of comparable molecular weights and polydispersities (90 kD, PD 1.2 and 82 kD, 
PD 1.1, respectively).  Commercially available, narrowly polydisperse PEO was 
included in the study as an uncharged control polymer for comparison to HPMA 
copolymers with quaternary ammonium charges.  The ratio of Kfc2 to Kfc1 is 
significantly decreased in the presence of both 10P(TMA)Cl and PEO, indicating 
a role for copolymer administration to distressed vascular endothelium and 









Figure 3.9. Mouse whole lung capillary filtration coefficient (Kfc) for lungs 
perfused with buffer alone (control, black bar), 1% PEO (grey bar), or 1% 
10P(TMA)Cl (hatched bar).  A significant reduction in Kfc occurs when lungs are 
perfused with either PEO or 10P(TMA)Cl with a lower mean Kfc observed in the 
presence of targeted copolymer.  
















 The development of water-soluble biomimetic copolymers that target the 
endothelial glycocalyx may be useful both as a tool to characterize 
mechanotransduction pathway(s) in vitro and as a prototype for developing  
clinical compounds to improve capillary barrier function during vascular 
inflammation.  Cationic copolymers have historically been used as gene delivery 
platforms and may be composed of primary or tertiary amines or quaternary 
ammonium groups (41, 47, 53).  We choose quaternary ammonium structures in 
order to minimize cellular activation and uptake by eliminating the ability for 
covalent bond formation, as quaternary ammonium does not possess a lone pair 
of electrons. We have previously shown the ability of HPMA-TMA Cl copolymers 
to bind to the endothelial surface and demonstrated an enhancement of barrier 
function and minimal cytotoxicity (54). The lowest mol% of quaternary ammonium 
in copolymers used in previous studies was 40 mol%; however, in present 
studies we are able to show the therapeutic benefit of this copolymer with a lower 
overall charge density (e.g., 10-20 mol% TMA Cl composition).  The benefit to 
lowering charge density is that there is a subsequent increase in cell viability as 
we have shown in previous LDH-release cytotoxicity assays (54) and as has 
been shown also by Reschel et al. (53). 
 In shear-induced hydraulic conductivity assays, a significant decrease in 
the shear-induced cell response is seen in cells pretreated with 20P(TMA)Cl 
(Figure 3.5). All of the Lp experiments display the characteristic “sealing” 




60 minutes of exposure to the pressure differential.  The sealing effect was not 
affected by any of the polymer treatments since the baseline control and 
treatment Lp values are not significantly different during the first 60 minutes (data 
not shown). Three polymers were tested on endothelial monolayers, each 
polymer composed of the same overall charge density (20 mol%) but differing 
molecular weights and distributions: 20P(TMA)Cl is a polydisperse copolymer 
(PD 1.8), 20P(TMA)Cl-F3 is a high molecular weight fraction of 20P(TMA)Cl (135 
kD, PD 1.1) and 20P(TMA)Cl-F5 is a low molecular weight fraction (24 kDa, PD 
1.2; characterization data is given in Table 3.1).  Both fractions have a lower 
polydispersity than 20P(TMA)Cl.  Figures 3.5 A – C show that shear-mediated 
hydraulic conductivity is significantly reduced in endothelial monolayers treated 
with each copolymer.  In Figure 3.6, the hydraulic conductivity output data for 
each polymer-treated monolayer were normalized to their respective control 
monolayers and compared. We show a significantly higher values for M 
generated from monolayers treated with 20P(TMA)Cl-F3, the 135 kDa 
copolymer. The molecular weight of linear polymers is often an indicator of the 
hydrodynamic radius of a macromolecule, whose influence on 
mechanotransduction has not been well defined.  We conclude that larger 
macromolecules have a greater protective effect against shear-mediated barrier 
damage. 
 Previously, we reported a significant decrease in pressure-mediated 
hydraulic conductivity in the presence of 1 mg/mL 40P(TMA)Cl (54), a copolymer 




previously demonstrated that increases in hydraulic conductivity are coincident 
with cellular increases in nitric oxide production (70) and are therefore indicative 
of the activation of mechanotransduction pathways.  In Figure 3.7 A, the 
administration of 20P(TMA)Cl to endothelial monolayers significantly reduces 
pressure-mediated hydraulic conductivity when compared to control monolayers 
receiving no treatment and that 20P(TMA)Cl significantly reduces peak 
normalized Lp levels, generated after 30 minutes at 30 cm H2O pressure, to the 
same levels as are generated when cells are incubated with the nitric oxide 
synthase inhibitor, L-NAME.  In Figure 3.7 B, we showed that these same cells 
generated significantly less nitric oxide in the presence of 20P(TMA)Cl than in 
untreated control cell monolayers when the media above the cells in these 
experiments was assayed for nitric oxide metabolites. There was no significant 
difference in NO production detected between groups treated with L-NAME and 
20P(TMA)Cl, however, this does not necessarily prove that 20P(TMA)Cl 
attenuates mechanotransduction through nitric oxide-dependent pathways, only 
that copolymer administration attenuates mechanotransduction.  Power analysis 
suggests that in order to elucidate a difference among 20P(TMA)Cl and L-NAME 
treated groups, the sample size would need to increase to 100 to have an 85% 
chance of seeing a difference between the groups.  As a sample size of this 
magnitude is both cost- and time-prohibitive, an alternative method of 
experimentation would need to be employed.  We do, however, conclusively 




thus indicating that copolymers improve endothelial barrier function by inhibiting 
cell signaling pathway(s) that induce mechanotransduction. 
 In order to determine polymer behavior in a whole lung model, high 
molecular weight fractions of 10P(TMA)Cl and polyethylene oxide (PEO) were 
perfused through an isolated perfused mouse lung model and the whole lung 
filtration coefficient was measured before and after polymer treatment.  
Perfusions of mouse lungs with 10P(TMA)Cl significantly decreased Kfc2/Kfc1 and 
thus reduce the pressure-induced permeability response in comparison to lungs 
receiving no treatment. We compared 10P(TMA)Cl to PEO, which carries no 
formal charge and is comparable to the HPMA backbone in water solubility and 
limited toxicity.  Both polymers are high molecular weight, low polydispersity, and 
are able to significantly reduce the capillary filtration coefficient when compared 
to controls receiving no polymer perfusion.  The protective effect of PEO in 
endothelial barrier regulation has been shown in transendothelial resistance 
studies and is reported in literature (81).  However, in an in vivo situation, a 
targeting moiety is necessary to anchor a therapeutic copolymer to the 
endothelium for any length of time that extends beyond transient contact. 
 The second optimization step of 10P(TMA)Cl was to reduce its 
polydispersity since in previous experiments we observed an increase in 
pulmonary artery pressure after perfusion with a polydisperse formulation of 
40P(TMA)Cl (Mw 54 kD, PD 1.8; data not shown).  We hypothesized that the 
cause of the increase in pulmonary artery pressure was that low molecular 




contraction of underlying smooth muscle cells.  The conclusion is that increasing 
molecular weight and reducing polydispersity improves vascular retentions, 
maintains normal pulmonary artery pressure (PPA2/PPA1 = 1.1, data not shown) 
and is able to reduce Kfc2/Kfc1 in whole lung studies.  
 
3.6 Conclusion 
 In this study we demonstrate the ability of water-soluble, biomimetic 
HPMA-based cationic copolymers to attenuate both shear- and pressure-
mediated increases in hydraulic conductivity across endothelial monolayers and 
that higher molecular weight copolymers have greater barrier protection 
properties.  We demonstrate a reduction in nitric oxide production in the 
presence of hydrostatic pressure in cells pretreated with 20P(TMA)Cl, suggesting 
a mechanism for the reduction in cellular response that impedes 
mechanotransduction.  Here we lay the ground work for the use of copolymers in 
research to gain greater understanding of the mechanism involved in endothelial 
mechanotransduction and show the potential for biomimetic targeted polymers to 
be used clinically in the treatment of states of enhanced permeability.  To this 













E-SELECTIN TARGETED COPOLYMER TO ATTENUATE 
 






 The efficacy of copolymer delivery to areas of acute vascular inflammation 
to enhance barrier function has been demonstrated in previous chapters.  In this 
chapter, cationic side chains are replaced with a targeting mechanism on the 
polymer to optimize delivery of polymer specifically to inflamed endothelium.  
Previously, we have used trimethylammonium chloride-HPMA copolymers to 
bind to negatively charged endothelium, however; this approach is for 
mechanotransduction research purposes only and can not represent a clinically 
viable therapy.  For this purpose, a targeting moiety that binds to E-selectin has 
been incorporated and is hypothesized to reduce the deleterious effects of acute 
inflammation by both dampening mechanotransduction and blocking leukocyte 
adhesion to the capillary wall.  In this section, we introduce an HPMA-peptide 






 In Chapters 2 and 3, the benefit of cationic copolymer delivery to inflamed 
vascular endothelium is demonstrated in both in vitro and ex vivo models.  
Cationic copolymers are able to reduce capillary permeability under conditions of 
pressure- and shear-mediated barrier stress, in the presence of inflammatory 
cytokines, and in whole mouse lungs subjected to high pressure.  In this chapter, 
we refine the copolymers’ targeting capacity to selectively target E-selectin, the 
receptor protein responsible for leukocyte binding, which is upregulated during 
acute inflammation.  The HPMA backbone is retained for its ability to intercalate 
into the endothelial glycocalyx to turn off mechanotransduction via cell signaling 
pathway(s). 
 The properties of E-selectin are reviewed extensively by Barthel et al. 
(60).  Briefly, E-selectin is a 64 kDa protein that is synthesized de novo in 
endothelial cells in response to inflammatory cytokines and is upregulated to the 
cell surface 2-6 hours after inflammatory insult.  It is responsible for the 
recognition of leukocytes and the mediation of early rolling events that preclude 
extravasation.  E-selectin has also been implicated in the increased permeability 
of the endothelial barrier via physical interactions with cytoskeletal proteins or 
changes in the shape of endothelial cells (60).   
 Leukocytes are carriers of sialyl lewis x, a well-documented ligand for E-, 
L-, and P-selectin (86-88).  Sialyl lewis x is a tetrasaccharide composed of sialic 
acid, fucose, galactose, and glucuronic acid.  Lowe et al. (63) determined that 




express human !1,3/4 fucosyltransferase, which induced cells to display sialyl 
lewis x.  Transfected cells then bound to E-selectin, thus implicating sialyl lewis x 
as the ligand (63).  The enzymatic removal of sialic acid via neuraminidase has 
been shown to decrease the affinity of E-selectin for the ligand (89, 90), thereby 
demonstrating the necessity of the sialic acid moiety.  In designing sialyl lewis x 
mimics, the positioning of the sialic acid carboxyl is conserved (91) along with 
fucosyl hydroxyl groups (91, 92). 
 The use of sialyl lewis x and its analogs, either free or conjugated to 
polymers, has been explored for cancer therapy (1, 32), in vivo imaging of areas 
of acute inflammation and/or tumor growth (57, 93), and anti-inflammatory drug 
delivery (86).  The ability of sialyl lewis x to block leukocyte binding to the 
endothelial surface has been explored as a treatment for vascular permeability 
as a result of ischemia/reperfusion injury (94) since leukocyte adhesion is one of 
the important early events that leads to pulmonary injury.  Mulligan et al. (59) 
explored the deleterious effect of neutrophil activation and contact with the 
capillary wall and demonstrated the significant protective effect that sialyl lewis x-
conjugated oligosaccharide intravenous infusion had against IgG immune 
complex-induced E-selectin-dependent lung injury (59). 
 A limiting factor in the use of carbohydrates is the time and expense 
required for synthesis.  The use of a peptide analog to sialyl lewis x that targets 
E-selectin is beneficial in that it can be made to increase bioavailability by 
extending the in vivo half-life of the analog via straightforward modifications, can 




scaffold.  Sialyl lewis x forms weak attachments with E-selectin, in keeping with 
its function to transiently recruit leukocytes to be tethered more tightly to 
adhesion molecules.  The binding affinity of sialyl lewis x is in the mM range (95) 
where peptide analogs to sialyl lewis x can be designed with increased ligand 
affinity for E-selectin (32, 91). In this work, we present a novel therapy for the 
treatment of vascular inflammation and demonstrate the ability for a peptide-
conjugated polymer to bind to immobilized E-selectin. 
 
4.3 Materials and methods 
4.3.1 Copolymer synthesis/characterization 
 Polymer precursor, composed of primary amine groups and fluorescein, 
was synthesized by radical solution polymerization of N-(2-
hydroxypropyl)methacryalamide (HPMA), N-(3-aminopropyl)methacrylamide 
(MA-AP) and 5-3-(methacryloylaminoropyl)thioureidyl fluorescein 
(MA-FITC, mol ratio 92 : 7 : 1) in methanol. The concentration of comonomers in 
the polymerization mixture was 12.5 wt% with 0.56 wt% AIBN and 0.04 wt% 
mercaptopropanoic acid (MPA). Radical polymerization was allowed to proceed 
in sealed ampoule under nitrogen atmosphere at 50ºC for 24 hours.  The polymer 
was first precipitated into acetone and then purified by dialysis. The yield was 
400 mg (62 wt%). The molecular weight (24 kD, 1.6 PD) was determined on a 
Superose 6 column in PBS using AKTA FPLC (GE Healthcare) equipped with 
UV, RI and light scattering MiniDawn (Wyatt Inc.) and calculated by ASTRA 
software (Wyatt, Inc.).  The SEC profile of the polymer precursor containing NH2 








Peak limits (min)  32.164 - 48.022 
dn/dc (mL/g)   0.170 
Polydispersity 
  Mw/Mn   1.403(2%) 
  Mz/Mn   1.994(2%) 
Molar mass moments (g/mol) 
  Mn   1.704e+4(1%) 
  Mp   1.559e+4(0.6%) 
  Mv   n/a 
  Mw   2.390e+4(0.7%) 
  Mz   3.398e+4(1%) 
 
 
Figure 4.1. Size exclusion profile and characterization data for the polymer 
precursor P(FITC)NH2 before maleimide conjugation. The green trace represents 
UV data collection, the red line is light scattering data, and the blue line is the 
refractive index profile.  Profiles are generated using AKTA instrumentation, 
ASTRA MiniDawn software, and a Superose 6 column in acetate buffer (0.25 M 
CH3COONa, pH 6.5). 
 
mol%) as determined by UV (borate buffer pH 8.5, molar extinction coefficient 
78,000 M-1 cm-1) and 0.46 mmol/mg (6.9 mol%) primary amine groups 
determined by ninhydrin method using amine monomer as the calibration 
standard. 
 To incorporate the maleimide groups, the polymer precursor (100 mg, 




maleimidomethyl]cyclohexane-1-carboxylate (SMCC, 27 mg, 0.08 mmol) and 
diisopropylethylamine (DIPEA, 15 mg, 1.7 mmol) in 1.5 ml dimethylformamide 
(DMF) for 24 hours. The reaction mixture was precipitated into acetone/Et2O 
(3:1) and purified on Sephadex LH-20 column in methanol.  The yield was 90 mg 
(90 wt%). The molecular weight of maleimide-containing polymer (29 kDa, PD 
1.6) was determined using Superose 6 column in 0.1 M acetate buffer, pH 6.5, 
with 30% acetonitrile using P(HPMA) calibration samples (see Figure 4.2 for SEC 
profile and MiniDawn characterization data). The maleimide content was 0.37  
mmol/g (5.6 mol%), which was determined by reacting different concentrations of 
polymer with an excess of thiol (glutathione) followed by determining the residual 
SH by Ellman’s reagent (96).  The molar ratio of the highest concentration was 
Mal : SH : Ellman’s = 1 : 3 : 25. 
 
4.3.2 Solid phase peptide synthesis  
 Amino acids were purchased in their protected forms and used directly for 
solid phase synthesis without further purification.  Peptide sequences ESBP (Ac-
CDITWDQLWDLMK-NH2) and SCRM (Ac-CKMIDWTWLQLDD-NH2) were 
synthesized according to solid phase protocol (97) on Rink-Amide resin, which 
yields a C-terminal amine.  Sequence and copolymer data are available in Table 
4.1. The N-terminus was acetylated using acetic anhydride as a final step.  The 
nascent peptides were dried overnight then cleaved from the resin with a mixture 
of trifluoroacetic acid (81% v/v), water (11.5% v/v), phenol (5% w/v), and 
ethanedithiol (EDT, 2.5% v/v) to yield the sequences ESBP and SCRM.  The 













 Peak 1 
Peak limits (min)  32.165 - 49.040 
dn/dc (mL/g)   0.170 
Polydispersity 
  Mw/Mn   1.572(2%) 
  Mz/Mn   3.235(2%) 
Molar mass moments (g/mol) 
  Mn   1.857e+4(2%) 
  Mp   1.849e+4(0.3%) 
  Mv   n/a 
  Mw   2.919e+4(0.7%) 
  Mz   6.007e+4(2%) 
 
Figure 4.2. Size exclusion profile and characterization data for the polymer 
precursor P(FITC)MAL after maleimide conjugation. The green trace represents 
UV data collection, the red line is light scattering data, and the blue line is the 
refractive index profile.  Profiles are generated using AKTA instrumentation, 
ASTRA MiniDawn software, and a Superose 6 column in acetate buffer (0.25 M 











Copolymer characterization data 
 
 
                   
Name   Peptide sequence   Molecular Peptide FITC  Weight %  Mol%  
        weight, content content  
        kDa,  (PDI) (mmol/g) (mmol/g)      
P(FITC)ESBP Ac-CDITWDQLWDLMK-NH2 29(1.6) 0.16  0.06  33   3.5 
P(FITC)SCRM Ac-CKMIDWTWLQLDD-NH2 29(1.6) 0.12  0.06  25   2.3  







precipitated in cold ether.  The product was dissolved in water and 
lyophilized.  The molecular weight and purity of each peptide was verified by 
MALDI-TOF mass spectroscopy (see Figure 4.3 and Figure 4.4 for 
mass/charge ratio data).  Crude peptide was purified by HPLC reverse phase 
semipreparative C12 column with H2O/acetonitrile and 0.1% trifluoroacetic 
acid as mobile phase (Figure 4.5).   
 
4.3.3 Polymer-peptide conjugation  
 Polymer precursor containing maleimide groups (15 mg, 5.7 !mol 
maleimide) was dissolved in 75 !l DMF.  ESPB or SCRM peptide, containing 
cysteine (4 mg, 2.3 !mol), were each dissolved in 40 !l DMF and incubated 
for 15 min with 40 !l Tris-(2-carboxyethyl) phosphine hydrochloride 
(TCEP, 10 mM in 50 mM HEPES buffer, pH adjusted to 7.0). The peptide 
solution was added dropwise into polymer solution and stirred for 2 hours at 
room temperature and overnight at 4ºC.  Nonbound peptide was separated 
from the polymer on PD10 column in PBS buffer. Incorporation of peptide is 
evaluated by UV spectroscopy using the molar extinction coefficient for 
tryptophan (5,500 M-1cm-1) (98).  Peptide content was found to be 0.163 
mmol/g (3.5 mol%, 34 wt %) for P(FITC)ESBP and 0.121 mmol/g (2.3 mol%, 
25 wt%) for P(FITC)SCRM.  Data for complete polymer peptide conjugate is 





Figure 4.3. Mass spectrum of purified ESBP peptide sequence.  The mass peak at 1708 correlates with the projected 





Figure 4.4. Mass spectrum of purified SCRM peptide sequence.  The mass peak at 1708 correlates with the projected 





Figure 4.5. Analytical HPLC profiles of A) ESBP conjugated to AF350 and B) 
buffer only.  Signals are, from top to bottom traces, collected at 220, 280, and 
320 nm, respectively.  Profiles are generated on C6 reverse phase column in 
water and acetonitrile with 0.01% TFA.  In Figure A, the peak at 5.196 minutes is 
the peptide.  Figure B shows that peaks beginning at minute 16 are inherent in 






 Recombinant human E-selectin (50 !g) was dissolved in cold PBS (0.5 
mg/mL) and E-Z Link NHS-PEG4-biotin (NPB, 5.05 !L, 1.7 mM) in cold PBS was 
added (biotin:E-selectin 10:1).  The reaction was allowed to proceed for 4 hours 
on ice.  Unreacted NPB was separated from conjugated E-selectin-PEG-biotin 
(EPB) by NEP-5 column (Sephadex G25) against PBS.  EPB binding to microtiter 
plates was confirmed using a 20x serial dilution of anti-CD62 E-selectin antibody 
(0.2-100 !L) in wells containing either immobilized E-selectin or blocking serum 
only.  The primary antibody was washed extensively and incubated with a 
fluorescein-labeled secondary IgG (DyLight 488, Jackson Immunoresearch). 
Fluorescence was analyzed immediately using microtiter plate reader (Tecan, 
Mannedorf, Switzerland) at optimized gain with excitation wavelength 488 nm 
and emission wavelength 535 nm. 
 
4.3.5 Peptide specificity  
 NeutrAvidin microtiter plates (Pierce Chemical, lower limit of biotin 
detection 5 ng/mL) were washed 3 times in wash buffer (25 mM Tris, 150 mM 
NaCl, pH 7.2, with 0.1% BSA and 0.05% Tween 20) and 10 !g/mL of NPB was 
added to each well.  Plates were incubated for 2 hours at room temperature then 
overnight at 4ºC.  Plates were subsequently washed three times in wash buffer 
and blocked for 1 hour with a solution of 10% donkey serum in PBS.  A serial 
dilution of P(FITC)ESBP or P(FITC)SCRM was performed in 1% donkey serum 
and reacted with bound E-selectin for 20 minutes.  Polymer solutions are washed 




donkey serum for analysis.  Fluorescence was measured immediately using a 




4.4.1 Peptide and polymer synthesis and characterization   
 The polymer P(FITC)ESBP is conjugated to an E-selectin binding peptide 
sequence (ESBP) that is the targeting peptide designed to interact with E-
selectin (E-Selectin Binding Peptide) and SCRM is the peptide sequence 
composed of the same amino acids but randomized to serve as a non-binding 
control.  Peptides were N-acetylated and C-amidated to confer greater blood 
stability to peptides. 
 The polymer precursor was synthesized in two steps.  A synthesis scheme 
is presented in Figure 4.5.  In the first step, HPMA, fluorescein, and aminopropyl 
monomers were polymerized to yield a polymer precursor composed of primary 
amine groups that function as reactive side chains for maleimide incorporation.  
The molecular weight was 23 kDa (PD 1.4, Figure 4.1).  The amine content of the 
polymer precursor was determined to be 0.046 mmol/g (6.9 mol%) and 0.056 
mmol/g (0.85 mol%) was determined for fluorescein. 
 In the second step, primary amines incorporated into the precursor were 
reacted with SMCC to yield maleimide reactive groups.  The molecular weight of 
the polymer precursor was measured by SEC to be 29 kD (PD 1.6, Figure 4.2).  












conjugation is common due to disulfide crosslinking. Peptides were conjugated to 
maleimide-containing side chains on the polymer precursor via the peptide thiol 
located on the N-terminal cysteine.  This approach was taken to minimize 
allosteric conjugation to the polymer since the cysteine thiol is the only available 
reactive group to maleimide in the polymer mixture. 
 
4.4.2 Peptide specificity  
 Peptide specificity for E-selectin was shown using streptavidin-coated 
plates onto which biotin-labeled E-selectin was immobilized.  Protein 
immobilization was confirmed by the reaction of an anti-E-selectin antibody and 
an Alexa 488-conjugated secondary antibody fluorescent IgG to immobilized E-
selectin (Figure 4.6).  Blocking the plates with 10% donkey serum reduced the  
nonspecific interactions between the polycarbonate microtiter wells and 
antibodies.  Figure 4.6 shows an increase in antibody signal in plates coated with 
immobilized E-selectin than in plates containing no protein.   
 To determine the specificity of P(FITC)ESBP for E-selectin, wells 
containing immobilized E-selectin were blocked then incubated for 20 minutes 
with either P(FITC)ESBP or P(FITC)SCRM.  Polymers were washed extensively 
from the plates and residual fluorescence was measured (Figure 4.7).  To 
demonstrate that polymers were not binding nonspecifically to wells, polymer 
was incubated in serum-blocked wells containing no E-selectin (DS/ESBP or 
DS/SCRM, Figure 4.7).  There was a significantly higher increase in polymer 
signal when P(FITC)ESBP was incubated with E-selectin than from any other 









Figure 4.6. Antibody binding to immobilized E-selectin to show that E-selectin 
was present in wells during experimentation.  A serial dilution of anti-E-selectin 
antibody was incubated with immobilized E-selectin (Esel 1,2Ab;!) or wells 
containing only blocking serum (1,2Ab;").  Secondary antibody only was added 











Figure 4.7. Specificity of P(FITC)ESBP for E-selectin.  Increasing concentrations 
of P(FITC)ESBP or P(FITC)SCRM were incubated with immobilized E-selectin to 
test for copolymer specificity or blocking protein only to test for nonspecific 
interactions with substrate.  The ESBP conjugate (E-sel/ESBP, !) displayed 
significantly higher affinity for E-selectin than did copolymer conjugated with the 
scrambled sequence (E-sel/SCRM, ").  There was no difference between 
P(FITC)SCRM incubated with either E-selectin or substrate only (DS/SCRM, !) 






groups when polymer was incubated with blocking serum alone or when 
P(FITC)SCRM was incubated with E-selectin, thus demonstrating that the ESBP 
sequence is a ligand for E-selectin and that its polymer conjugate, P(FITC)ESBP, 
demonstrates specificity when compared to the scrambled sequence conjugate.  
 
4.5 Discussion 
 The use of sialyl lewis x as a targeting moiety has been explored for a 
variety of purposes (32, 60, 86, 93), however, the trend toward the use of 
carbohydrate analogs has largely shifted in favor of peptide targeting moieties as 
peptide synthesis is faster, delivers higher compound yield, and is less 
cumbersome than carbohydrate synthesis.  Herein, we describe a novel use for a 
copolymer-peptide conjugate that targets E-selectin to attenuate vascular 
permeability using a multifaceted approach.  The ESBP targets E-selectin, which 
is upregulated on the endothelial cell surface in the presence of acute 
inflammation.  Once the copolymer binds to E-selectin, it can block receptor 
binding sites, thereby attenuating the leukocyte tethering and rolling pattern.  
Lastly, the copolymer conjugate is hypothesized to turn off mechanotransduction 
via glycocalyx-HPMA interactions, which has been shown previously to reduce 
the cell-signaling cascade that is produced in the presence of mechanical stress.   
 The E-selectin binding peptide sequence used in these experiments was 
initially derived from phage display experiments (65) and has been used to target 
anticancer drugs (32) and imaging nanoparticles (6) to sites of E-selectin 
upregulation.  This lab has shown that HPMA copolymers that bind to inflamed 




and solute flux through capillary endothelial monolayers (54) and Beauharnois et 
al. have demonstrated the ability of sialyl lewis x-bearing oligosaccharides to 
competitively inhibit ligand binding to P- and L-selectins during hydrodynamic 
shear stress (99).  Taken together, we approach the mechanism of strengthening 
the lung capillary endothelial barrier with a multifaceted system.  
 Herein, E-selectin binding peptide (ESBP) is conjugated to HPMA via a 
thioether linkage facilitated by the addition of cysteine at the peptide C-terminus 
and the incorporation of maleimide reactive groups into the polymer precursor.  
The specificity of the reaction between maleimide and cysteine is exploited to 
increase E-selectin binding by ensuring that the entire peptide remains free of 
steric hindrance that may occur with a less site-directed approach.  The peptide 
was N-acetylated and C-amidated in order to provide additional protection 
against nonspecific proteases found in vivo.  There were found to be an average 
of 8 peptides per macromolecule of P(FITC)ESBP, which should increase the 
binding capability by multivalency effect (85).  In competitive binding assays that 
use sialyl lewis x as the inhibitor, HPMA conjugated to a similar E-selectin 
binding peptide and has yielded an IC50 of 6 nM (32).  The free peptide is 
reported to bind with an IC50 value of 5 !M (65). 
 The specificity of P(FITC)ESBP was determined by immobilizing E-
selectin on streptavidin coated microtiter plates.  Surface amines on E-selectin 
were exploited to bind a succinimidyl ester that was conjugated to a 29 Å PEG 
spacer that terminated with a biotin reactive group.  The addition of the 29 Å PEG 




been buried against the microtiter support wall.  The affinity of the peptide 
conjugate for E-selectin was tested by adding an increasing concentration of 
P(FITC)ESBP to wells with immobilized protein followed by an extensive wash 
step.  The data show that the fluorescence signal from P(FITC)ESBP increased 
with increasing polymer concentration in the well and no such increase was seen 
for either P(FITC)SCRM incubated with E-selectin or wells containing no E-
selectin that were incubated with either polymer (Figure 4.3). These controls 
eliminated the possibility that the copolymer was reacting nonspecifically to either 
E-selectin or the substrate.   
 
4.6 Conclusion 
 This chapter details the synthesis and binding specificity of an HPMA 
copolymer conjugated with a peptide that binds E-selectin.  This polymer design 
lays the foundation for future mechanotransduction research and a potential 
















CONCLUSIONS AND FUTURE WORK 
 
5.1 Conclusions 
 The research contained in this dissertation establishes the mechanistic 
foundations for developing a polymer-based treatment to attenuate pulmonary 
edema, a major complication of acute lung injury. We have shown that positively 
charged copolymers, designed to target the negatively charged endothelial 
glycocalyx, can enhance the capillary barrier by turning off mechanotransduction.  
Preliminary experiments, described in Chapter 2, focus on the development of a 
copolymer that demonstrates safety, endothelial surface binding, and efficacy in 
reducing the monolayer permeability to fluid and solute flux.  To demonstrate 
safety, we show that copolymers, composed of quaternary ammonium side 
chains, elicit very little cytotoxicity even at higher concentrations and are, 
therefore, a better prototype than copolymers with primary amine structures. 
HPMA was chosen as the comonomer due to its established characteristics as a 
water-soluble, nonimmunogenic substrate for polymer delivery (44, 45).  We 
have demonstrated the ability of positively charged copolymers to attach to the 




microscopy.  The ability of the polymer to reside on the cell surface with minimal 
internalization was shown by a clear line of delineation between the polymer on 
the cell surface and the actin cytoskeleton.   
 To demonstrate functional efficacy, quaternary ammonium based 
copolymers were utilized in a variety of in vitro assays.  In cytokine-mediated 
endothelial permeability, the addition of 40P(TMA)Cl reduced the flux of albumin 
through cell monolayers in the presence of the inflammatory mediator, 
bradykinin.  This reduction was taken as evidence that polymer administration 
can mitigate the passive diffusion of protein across the endothelium, which is a 
major component of vascular inflammation.  Both 20P(TMA)Cl and 40P(TMA)Cl 
reduced pressure-induced hydraulic conductivity through bovine and rat 
microvascular endothelial monolayers. This reduction in monolayer permeability 
paralleled a reduction of nitric oxide released from cells under identical 
mechanical stress.  This we take as evidence that polymeric contacts with the 
endothelial glycocalyx are able to attenuate mechanotransduction, or the active 
relay of signal(s) from extracellular mechanical forces to intercellular junctional 
proteins.   
 The next focus of experimentation was to optimize copolymers destined 
for potential pulmonary administration.  We made important observations 
regarding the characteristics that any polymer-based therapy must possess and 
the mechanism by which polymer administration strengthens the endothelial 
barrier.  For in vitro testing we used widely polydisperse copolymers.  In whole 




copolymers significantly increased pulmonary artery pressure, a side effect that 
would be deleterious in a clinical setting.  We hypothesized that the increase in 
pulmonary artery pressure was a result of one, or both, of two factors: low 
molecular weight copolymers were diffusing through the endothelial junctions to 
cause smooth muscle contraction or that the charge density of the polymer had 
surpassed a threshold and was causing aggregation of media proteins and a 
subsequent microvascular embolization.  Two modifications to the polymer were 
made: first, low molecular weight polymers were removed by fractionation and 
the charge density was reduced to 10 mol%.  The optimized polymer was 
administered to mouse lungs and a reduction in the capillary filtration coefficient 
was observed in the presence of either 10P(TMA)Cl or PEO, our control polymer 
of comparable geometry, water solubility and molecular weight.  We 
hypothesized that HPMA and PEO backbones used the same mechanism to 
reduce the capillary filtration coefficient, namely by dampening the mechanical 
stress experienced by the glycocalyx.  Collectively, these experiments validate 
the ability of a copolymer solution that reduce the flux of fluid and protein into 
pericapillary tissues in a whole lung model. 
 Cationic targeting moieties have been used to this point as a proof-of-
concept tool to illustrate the efficacy of copolymer contact with the glycocalyx to 
reduce mechanotransduction. Once polymeric treatment of vascular inflammation 
showed more promise as a viable therapy, optimization of the targeting moiety 
was a necessity.  Pleiotropic effects remain the primary concern with the 




ammonium targeting moieties were replaced with a peptide ligand for E-selectin, 
which is upregulated on endothelial cells 2-6 hours after inflammatory insult.  E-
selectin has been used in a variety of applications to target inflammation in a 
range of tissue types (6, 57, 93).  To this end, the HPMA backbone was retained 
and maleimide reactive groups were used to conjugate a cysteine-terminal 
peptide to the polymer precursor.  Copolymer bearing E-selectin binding peptide 
(ESBP), a 13-amino acid peptide sequence (CDITWDQLWDLMK), was tested for 
specificity on immobilized E-selectin and it was shown that the polymers bind to 
their target protein.  These experiments provide the basis for targeted polymer-
based compounds to inflamed endothelium that could be clinically relevant for 
the treatment for acute pulmonary edema and vascular permeability. 
 
5.2 Future work 
 There are two primary directions in which this research may be taken: 1) 
to further investigate the mechanism(s) of mechanotransduction, and 2) 
optimization of polymers as a viable clinical treatment for ALI/ARDS. 
 
5.2.1 Mechanotransduction research 
 There is an irrefutable effect of copolymers on mechanotransduction. The 
mechanism(s) by which perturbations to the endothelial glycocalyx translate to 
downstream cell signaling and subsequent junctional opening remains unknown.  
The barrier-enhancing effect of copolymer-glycocalyx interaction has been 
proven in the presence of hydrostatic pressure and shear stress, the two vectors 




significant suppression of nitric oxide formation from monolayers treated with 
copolymer, which demonstrates that the barrier enhancing effect of copolymer 
administration takes place at the intercellular level and is not only a physical 
barrier effect.   
 The decrease in NO production in the presence of 20P(TMA)Cl is 
evidence that polymer administration has an effect on the cell signaling 
pathway(s) that enables mechanotransduction to alter cell-cell junction integrity.  
For example, the effect of shear stress and hydrostatic pressure on endothelial 
nitric oxide production is a well-documented phenomenon (8, 78, 83), however, 
the mechanism by which pressure and shear stress is first detected by the cell is 
largely unknown.  A possible approach to mechanism elucidation is visualization 
and quantification of junctional proteins in the presence of polymer and 
hydrostatic pressure and/or shear stress.  For instance, Thi et al. (15) have 
demonstrated the ability to visualize the intracellular rearrangement of 
cytoskeletal structural components and junction proteins under fluid shear stress 
using confocal microscopy.  This method of visualization can potentially elucidate 
the rearrangements of cellular components in the presence of copolymers to 
determine those that are involved in mechanotransduction signaling. 
 One significant question that arises from this research is how rigid a 
polymer needs to be in order to dampen mechanotransduction.  In our 
experiments, the only polymer backbone that was tested was HPMA.  P(HPMA) 
alone, without cationic side chains, was shown to reduce hydraulic conductivity in 




than did 40P(TMA)Cl.  The conclusion of this observation is that HPMA 
intercalating into the glycocalyx, effectively thickening the matrix on the cell 
surface, dampens mechanotransduction. The addition of PEO appeared to have 
a barrier strengthening effect in whole mouse lungs as well, although more 
replicates would be necessary to determine if a difference between HPMA and 
PEO backbones exists.  The use of a variety of linear, neutral, water-soluble 
polymers of differing flexibilities may give some insight into how the stiffness of 
the glycocalyx alters mechanotransduction. The persistence length is defined as 
the distance at which the correlation between the polymer vector and its length is 
lost and is therefore a measure of rigidity.  For example, PEO is known as a very 
flexible, dynamic polymer with a persistence length of 3.7 Å in water (100). It is a 
linear polymer composed of single bonds; its lack of side chains confers 
unrestricted motion and its periodic oxygen molecules give it excellent water 
solubility.  P(HPMA) may be predicted to be less flexible than PEO; its 
persistence length is reported to be 11 nm in aqueous solution (101), which may 
be attributed to the drag that its side chains may induce in polar solvent.  A 
saccharide-based linear polymer such as cellulose may be predicted to have 
even less flexibility (persistence length 14.5 nm (102)), thus allowing for a range 
of polymer types to be tested in contact with the glycocalyx.  The stiffness of the 
glycocalyx in the presence of polymer may be tested either by using atomic force 
microscopy (103) or magnetic beads in an applied torque (14), and the hydraulic 
conductivity system used in this research is an excellent tool to correlate the 




5.2.2 Clinical use optimization 
 The original intent for the development of biomimetic polymers that 
intercalate with the endothelial glycocalyx was to design a clinically applicable 
treatment to reduce vascular permeability, which occurs in conjunction with acute 
lung injury.  In order to be a viable treatment, some optimization of the polymer 
backbone and targeting side chains would be necessary. 
 In vivo, peptides are susceptible to serum-mediated damage such as 
enzymatic degradation, immunogenicity, and hydrolysis.  Enzymatic degradation 
usually begins at the administration site and may be so extensive that it 
completely hinders the intact peptide from reaching its target (104). Peptide 
conjugation to a water-soluble polymer increases the systemic half-life by 
sterically blocking enzymatic degradation (105-107), which is an excellent first 
line of peptide defense but does not render the peptide impervious to plasma 
protein-mediated attack.  A few modifications that may be made to the peptide 
targeting moiety to add stability are diastereomer substitution or terminal 
modifications, or the use of a non-peptide analog to sialyl lewis x. 
  The incorporation of D-amino acids may make peptides more stable in 
vivo as unsuitable protease substrates; however, their use may also render the 
peptide inefficient receptor agonists.  Recently, a peptide composed of 24 amino 
acid residues was altered by replacing two phenylalanine residues with their D-
conformers and the in vivo stability was measured.  The exchange of only 2 
residues extended the blood half-life by 25% (108). We hypothesize that this 




The particular sequence described in Chapter 4 was derived from a phage 
display experiment in which many peptides were discovered to bind to E-selectin.  
Each peptide sequence had four conserved residues (65).  These common 
residues, the fourth and eighth tryptophan and penultimate methionine plus the 
C-terminal carboxyl, correspond to reports on sialyl lewis x analog requirements 
for binding, namely pi stacking and carboxyl positioning (109).  Other residues on 
the peptide are not likely to be involved in receptor binding and therefore would 
be good candidates for D-amino acid substitution.  
 An approach taken in this research was to acetylate and amidate the N-
terminus and C-terminus of ESBP, respectively.  C-terminal amidation serves to 
protect the peptide from carboxy peptidase activity and acyl peptide derivatives 
have been shown to increase enzymatic stability in serum-containing media (110, 
111), however, even modified peptide half-life remains relatively short at 77 
minutes (110).  
 The use of non-peptide analogs to sialyl lewis x that bind E-selectin have 
been extensively explored (91, 92, 112, 113) as the main drawbacks to using 
sialyl lewis x is expense of materials and moderate E-selectin binding affinity.  
While the chemistry of such analogs tends to be cumbersome, it is often more 
simple than synthesis of the entire sialyl lewis x tetrasaccharide.  An advantage 
to synthetic compounds is the reduction in systemic protease activity increase, in 
vivo half-life and bioavailability, and higher binding affinity for E-selectin than its 




specificity differs between selectins. This aspect may be exploited through 
engineering to target a particular selectin of interest (113). 
 The advantages to using a polymer backbone such as P(HPMA) are long-
lasting circulation in the blood stream, limited toxicity, water solubility and ease of 
synthesis and conjugation (44, 45, 114).  High molecular weight nondegradable 
polymers, however, remain in circulation long after the desired effect has been 
attained and tend to accumulate in organs (115) and cellular organelles (32, 49).  
A solution to this problem is to use an enzymatically degradable polymer 
backbone with tailored degradation kinetics.  Many polymer designs conjugate a 
drug to a non-degradable polymer backbone by using a pH- or enzymatically 
degradable linker in order to release the drug at a controlled rate (116) and/or 
specific target area (117, 118).  This rationale may be exploited to synthesize a 
polymer of sufficient molecular weight to intercalate into the glycocalyx then be 
degraded over time as the acute inflammatory period passes.  Since our polymer 
construct is designed for systemic delivery, it should reach the lung vasculature 
within seconds if administered via the internal jugular vein.  A potential synthesis 
scheme would involve GFLG-di-methacrylamide monomers, obtained through 
solid phase peptide synthesis, that are polymerized with HPMA monomers and a 
chain transfer agent to keep the molecular weight of P(HPMA) low.  Reversible 
addition-fragmentation chain transfer (RAFT) polymerization should be used so 
that upon degradation P(HPMA) exits the system through renal clearance.  A 
polymer containing the GFLG linker has been shown to degrade by 80% after 48 




critical aspects of acute vascular inflammation.  The degradation rate may 
increase in the presence of an acute inflammatory response due to increased 
circulating levels of plasma proteases; the outcome of those studies, along with 
rheological testing to determine the threshold for crosslinking-mediated hydrogel 
formation, would dictate the optimal GFLG content. 
 A final optimization step would be to measure the distribution and 
pharmacokinetics of polymer adsorption and excretion.  A bolus of optimized E-
selectin peptide conjugated polymer, labeled with an MRI contrast agent such as 
Gd3+ (119), could be administered via jugular vein to a whole mouse model with 
induced pulmonary inflammation induced by high tidal volume ventilation.  
Polymer should be allowed to circulate and the mouse would be imaged using 
MRI to determine the percentage of the bolus that adheres to lung 
microvasculature.  The carotid artery would be cannulated and the outflow should 
be sampled for fluorescein-conjugated copolymer concentration over time.  An 
ideal delivery method is a bolus injection that maximally absorbs polymer to 
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